Regulation and Programming of Antibody Effector Function through IgG Glycosylation by Mahan, Alison Emilia
 
Regulation and Programming of Antibody Effector Function through
IgG Glycosylation
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 17, 2015 12:59:04 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13070040
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAARegulationandProgrammingofAntibody
EﬀectorFunctionthroughIgGGlycosylation
adissertationpresented
by
AlisonEmiliaMahan
to
TheDepartmentofMedicalSciences
inpartialfulfillmentoftherequirements
forthedegreeof
DoctorofPhilosophy
inthesubjectof
Virology
HarvardUniversity
Cambridge,Massachusetts
September2014©2014 -AlisonEmiliaMahan
Allrightsreserved.Dissertationadvisor: ProfessorGalitAlter AlisonEmiliaMahan
RegulationandProgrammingofAntibodyEﬀectorFunction
throughIgGGlycosylation
Abstract
Antibodiesarethedefiningcharacteristicofthehumoralimmuneresponse. Their
functionsarediverse,includingdirectneutralizationofpathogensandrecruitment
of other immune molecules or cells. While most successful vaccines induce pro-
tective neutralizing antibody responses, eﬀective vaccine-elicited neutralizing an-
tibodies against some pathogens, including HIV, HCV, malaria, and TB, remain
elusive. Thus, researchers have begun to focus on how vaccines can elicit strong
non-neutralizingantibodyfunctions,includingrecruitmentofinnateimmunefac-
torsforantibody-dependentcellularcytotoxicity,complementdeposition,andanti-
body-dependentphagocytosis. Theantibody’sconstantregion(Fc)mediatesmost
eﬀectorfunctionsthroughisotypeandsubclassselectionoralterationofthestruc-
ture of the Fc-attached N-glycan, which controls function with exquisite speci-
ficity. Glycanmodificationsarenaturallyinducedduringinflammatoryconditions
suchasautoimmunediseaseandnaturalinfectionhowever,thespecificsignalsthat
regulateFc-glycosylationremainunknown.
Thisdissertationsoughttounderstandhowantibodyglycosylationisregulated
andhowitcanbeprogrammedthroughvaccination. Todothis,wefirstdeveloped
a technique to analyze antibody glycan structures both of bulk Fc and antigen-
specific antibodies. Using this technique, we observed significant modulation of
antibodyglycansduringviralinfectionaswellasinvaccine-elicitedantibodies. To
iiiDissertationadvisor: ProfessorGalitAlter AlisonEmiliaMahan
identify specific signals important for altering the antibody glycan, we transcrip-
tionallyprofiledstimulatedBcellsandidentifiedasetofinnateandadaptivestim-
uli that regulate the genes responsible for antibody glycosylation. The results de-
scribed in this dissertation begin to define the specific mechanism(s) by which
infectionandvaccinationmodulateantibodyglycosylationtoelicitfunctionalan-
tibodiesthatcanultimatelyprovideeﬀectiveandsustainedprotectionfrominfec-
tion.
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Introduction
The immune system is a complex and eﬀective mechanism to protect a host
from pathogen. When it is in perfect working order, it can eliminate dangerous
foreign entities while ignoring host cells and proteins. However, when it fails, as
in the case of auto-reactivity or chronic infection, it is important to understand
the factors that cause this failure so that it can be prevented or corrected. One of
the most significant examples of immune failure is the rampant and uncontrolled
infectionofmillionsofpeoplewithpathogensagainstwhichtherearenoeﬀective
vaccines, such as human immunodeficiency virus (HIV), tuberculosis (TB), and
malaria. In order to develop better strategies for vaccine development, we mustunderstand how the immune system works naturally and how we can direct it to
elicitprotectiveresponsesaftervaccination.
1.1 Theimmunesystem
1.1.1 Theinnateresponse
The mammalian immune system has two major mechanisms of action, the fast
acting, but non-specific innate system, and the slow to activate, but highly spe-
cific adaptive response. Cells of the innate system are first to respond to invad-
ing pathogens, and they can recognize infection through non-specific signals of
danger, such as common bacterial proteins or carbohydrates and the presence of
foreign nucleic acids [222]. These signals are recognized through pattern recog-
nitionreceptors, ofwhichthebestunderstoodarethetoll-likereceptors(TLRs),
a family of receptors expressed on a variety of cells, including cells of the innate
and adaptive immune system [215]. Each of the ten human TLRs recognizes a
specific molecular pattern commonly found on bacterial or viral pathogens, but
not expressed by mammalian cells (Table 1.1) [10]. Once these receptors recog-
nizetheirtarget,theyactivatecellstorecruitadditionalcellsoftheinnateimmune
system[9].
Oncecellsoftheinnateimmunesystemrecognizethepresenceofpathogens,a
cascadeofsignalingmoleculescalledcytokinesareproducedtorecruitadditional
innate cells to the site of infection [134]. The innate response is rapid because
it is mediated by potent cytokine signals, which initiate inflammation, however
2Table1.1: Toll-likereceptors
Humantoll-likereceptors,theirtargetsandcellularlocalization[1].
Receptor Target SubcellularLocation
TLR1/2 Bacteriallipopeptides Plasmamembrane
TLR2 Bacterial peptidoglycan and
lipoprotein. Viral hemagglu-
tinin
Plasmamembrane
TLR3 ViraldoublestrandedRNA Endosomalmembrane
TLR4 Gram negative bacterial
lipopolysaccharide(LPS)
Plasmamembrane
TLR5 Bacterialflagellin Plasmamembrane
TLR2/6 Bacteriallipopeptides Plasmamembrane
TLR7 ViralsinglestrandedRNA Endosomalmembrane
TLR8 ViralsinglestrandedRNA Endosomalmembrane
TLR9 Viral and bacterial unmethy-
latedCpGDNA
Endosomalmembrane
3this response is also non-specific and can cause general inflammation and even
allergy, since the danger signals detected by innate cells may be present on non-
pathogenic organisms [204]. Additionally, some pathogens have evolved mecha-
nismstoevadetheinnateresponsethroughmimicryofselfordown-regulationof
innatesignals[83]. Thus,whiletheinnatesysteminessentialintheearlystagesof
infection,theadaptiveresponseisoftenrequiredtoeliminateinfectiousagents.
1.1.2 Theadaptiveresponse
During the fast response of the innate system, innate cells ingest pathogens and
bringthemtospecializedimmuneorganstoactivatetheadaptiveresponse. Inthe
lymph nodes, innate cells present digested pathogens to cells of the adaptive im-
mune system, which are activated in a pathogen-specific manner [1]. Where the
innate system expresses a set of receptors that have a limited ability to bind to a
broadsetofmoleculesgenerallyassociatedwithpathogens,theadaptivecellshave
exceptionally specific receptors. The two major players of the adaptive response,
BandTcells,createthisspecificitythroughtheirhighlyvariablereceptors: Band
T cell receptors (BCR and TCR, respectively). Adaptive lymphocyte receptors
are unique to each clonal population of cells; a product of genetic rearrangement
ofthereceptorgenes[154]. Withineachadaptivecell,randomassortmentofthe
antigen-receptor alleles generates a unique receptor binding site [98], which in B
cells,servesasaprecursortosecretedantibody,whosebindingspecificitywillma-
tureduringactivationofthehumoralimmuneresponse[148].
41.2 Thehumoralimmuneresponse
While the immune system is broadly classified into the innate and adaptive re-
sponses,thehumoralresponsecanbridgethesecategoriesbylinkingthepathogen
specificity of the adaptive response to the speed and force of the innate response.
The hallmark of the humoral response is the immunoglobulin molecule, or anti-
body, which is produced by B cells that have been stimulated in the presence of
theirantigen-specificpathogen.
1.2.1 Bcelldevelopment
B,Tandnaturalkiller(NK)cellsalldevelopfromthecommonlymphoidprogen-
itor (CLP), which matures from the pluripotent hematopoietic stem cells of the
bonemarrowandfetalliver[1]. TheCLPcanmatureintoapro-Bcell,whichisan
immaturelymphocytewithnoantigen-specificcellularreceptors[79]. Thesecells
develop into pre-B cells and begin to express the non-specific pre-antigen recep-
tor,whichisrequiredforcontinueddevelopment[187]. Oncethepre-Bcellcom-
pletesitsdevelopment,itproliferatestoproduceaclonalpopulationofcells,which
mature to express complete antigen receptors [135]. The production of antigen-
specificreceptorsoccursthroughgeneticrearrangementoftheheavychainofthe
immunoglobulinmolecule[131]. Atthisstage,geneticrearrangementoftheimm-
unoglobulin(Ig)locusallowsforthegenerationofadiversesetofuniqueantigen
receptors within the expanding pre-B cell population [85]. Upon selection of an
immunoglobulinlightchainallele,acompleteBcellreceptor(BCR)isgenerated
5[148]. TheresultingimmatureBcellissubjecttoselection, wherebystrongaﬃn-
ity of the BCR for self-generated antigens results in the apoptotic deletion of the
cell [187]. Weak BCR aﬃnity, however, drives the cell to continue development
intoamatureBcell[1]. Atthispoint,thematureBcellexitsthebonemarrowinto
the lymphatic circulation to transit to lymphoid organs including the spleen and
lymphnodes[148]
1.2.2 Antigen-specificactivationofBcells
OnceaBcellismature,itremainsnaïveuntilitisstimulatedthroughrecognition
of its cognate antigen [1]. Recognition of antigen by the B cell can occur in a T-
cell dependent or -independent manner. In T-dependent activation, a B cell rec-
ognizesitsantigenthroughitsBCRandpullsattachedproteinorpathogeninside
itselffordegradationandpresentationonsurfacereceptorscalledmajorhistocom-
patibility complexes (MHC) [245]. Mature, antigen-specific T cells recognize
MHCembeddedantigenandactivatetheBcellthroughcytokineproductionand
activation of CD40 with its T cell expressed ligand (CD40L) [1]. This combina-
tionofsignalsactivatestheBcelltoproliferateandmatureitsBCR.Maturationof
theBCRinvolvesfurthergeneticmutationoftheIglocuswithineachcelltocreate
arepertoireofuniqueBCRswithintheexpandingBcellpopulation[85]. Eachof
thesereceptorswillbetestedagainstthepathogenandonlythosecellsexpressing
BCRs with strong aﬃnities will be maintained and expanded [187]. This system
allows for the generation of an enormous population of unique antigen-specific
cells,eachwithastrongaﬃnityforspecificantigensexpressedbythepathogen.
6T-cellindependentactivationoccurslessfrequentlyandrequiresahighlyrepet-
itive, or polyvalent, antigen, which allows for multiple molecules of the BCR to
bind the antigen and link together at the surface of the B cell. This linking allows
the receptors to interact with each other and initiate an activating signal strong
enoughtoovercomethelackofco-stimulatorysignalsfromTcells[1].
Both T dependent and independent activation of B cells results in the genera-
tionofsoluble,secretedimmunoglobulin(Ig),orantibody. Antibodyisgenerated
by the removal of the transmembrane domain of the BCR to generate a soluble
antigen-specificmoleculethatishighlyspecifictotheirantigenandareanimpor-
tant factor in eﬀective protection from pathogens [148]. Once an antibody pro-
ducing cell is generated, it can mature into a long-lived plasma cell, which will re-
turntothebonemarrowandmayliveaslongasitshost[1]. Additionally,memory
B cells are generated during the proliferative stages of B cell activation and these
remain in the circulation or reside in lymphoid organs in order to initiate a rapid
secondaryresponseintheeventofre-exposuretoitscognateantigen,forinstance
duringnewinfectionwithapreviouslyencounteredpathogen[1].
Aspartoftheirabilitytobridgeinnateandadaptiveimmunity,Bcellsexpressa
varietyoftheinnateTLRreceptors[25]. WhiletheparticularroleofTLRsignal-
inginBcellsisnotcompletelyknown,studiesinhumansandmicerevealageneral
increaseincellularTLRexpressionandactivationasBcellsdevelopfromnaïveto
mature [167]. In particular, B cell stimulation by TLR ligation induces prolifera-
tion,antibodyproductionandinhibitionofapoptosis,aswellasadrivingactivated
cellstodiﬀerentiateintoplasmacells[35,71,96]. ThiseﬀectofTLRsignalingon
7theadaptiveresponsehasledtosignificantinterestinelicitingTLRactivationdur-
ingvaccinationthroughtheuseofTLRagonistsasvaccineadjuvants[175].
1.2.3 Structureanddiversityofantibodies
Secretedimmunoglobulinscontaintwoidenticalunitsofbothheavyandlightchain
proteinsandcanbedividedintofunctionalunitsoftheFab(antigenbinding)and
Fc(crystallizable)fragments(Figure1.1A).TheFabfragmentcontainsthehighly
variable,geneticallymutatedregionsoftheheavyandlightchainsofimmunoglob-
ulin,whichinteractwithantigenanddefinethebindingspecificityoftheantibody
[197]. Incontrast,theFcfragment,whichcontainshalfoftheheavychain,isoften
referred to as constant since it has a set sequence and structure depending on the
isotypeandsubclassoftheIg[67].
Depending on the signals present during T-dependent activation of a B cell,
diﬀerent classes, or isotypes, of immunoglobulin molecules are produced [40].
Immunoglobulinisotypeisacriticaldeterminantofantibodyfunctionsinceeach
classmediatesdiﬀerentinteractionswithinnatecellsandimmunemolecules[160].
NaïveBcellsproduceIgM,whichisalowaﬃnity,high-avidityantibodyproduced
beforematurationoftheBCR[1]. ThelowaﬃnityofIgMiscompensatedforbyits
abilitytomultimerizeintopentamersorhexamers,whicharelinkedtogetherwith
the J chain linker, as shown in Figure 1.1B [1]. IgM molecules function primar-
ilythroughopsonization,wherebytheycoatpathogensandsignalimmunecellsto
destroythem[1].
ThepresenceofspecificcytokinesignalsduringBcellmaturationcandriveim-
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Ǒmunoglobulin class switching to produce IgA, IgG or IgE isotypes [1]. The IgA
can be produced as single units or as a dimerized form, connected through the
J chain linker (Figure 1.1B) and is important for protection of mucosal barriers
suchasthegut,nose,andreproductivetractbecauseitiseasilytransportedacross
epithelial borders into mucosal surfaces [1]. IgE is generated in the presence of
specific cytokines that during B cell maturation and is important for clearance of
helminthinfection,thoughitismostoftenassociatedwithallergicresponses[1].
GenerationoftheIgGisotypeisthemostcommonresponsetoBcellactivation
andoccursmostoftenthroughTcell-dependentactivation,thoughitissometimes
elicitedafterT-independentactivation[211]. CirculatingIgGconcentrationscan
be as high as 10 mg/ml in healthy human blood serum and this molecule has a
variety of important immunological roles [1]. Once the IgG isotype is selected,
furthersubclassselectioncangreatlyaﬀecttheactivityoftheantibody. Inhumans,
there are four IgG subclasses: IgG1, IgG2, IgG3, and IgG4, each of which has a
diﬀerent function and is produced at diﬀerent concentrations during an immune
response[102]. SinceIgGmakesupthevastmajorityofcirculating,high-aﬃnity
immunoglobulin, it is an important component of a protective adaptive immune
response[37,88].
1.2.4 FunctionsofIgG
The functions of IgG can be broadly classified into Fab- and Fc-mediated. The
bestrecognizedFab-mediatedfunctionofantibodiesisthatofneutralization. This
function is regulated primarily by the variability of the antigen-binding domain
10andisdependentonthebindingspecificityoftheFab. Neutralizationofapathogen
requires highly specific blocking of the viral or bacterial entry machinery to elim-
inate interaction with and/or entry into host cells [132]. Additionally, antibod-
iescanbinddirectlytopathogen-generatedtoxinstoneutralizepathogeniceﬀects
through specific binding [148]. While most existing vaccine strategies elicit pro-
tectiveneutralizingantibodies,vaccine-elicitedneutralizingantibodieshavenever
beengeneratedagainstsomepathogens,includingHIV,TBandmalaria[171]. In-
terestingly,althoughHIVneutralizingantibodiesareprotectiveinanimalmodels
of passive antibody transfer [142], they do not appear to protect the 10-30% of
humans who develop them naturally, likely because they are generated only after
yearsofinfection[88,196].
Independent of the antigen-binding domain, function and potency are medi-
ated by variation of the IgG constant region or crystallizable fraction (Fc), which
controls recruitment of innate immune cells [160], inflammatory signals [150],
andcomplementdeposition[105],andaswellasalteringtheantibody’shalf-lifein
thecirculation[20]. Thesefunctionsdonotnecessarilyrelyonthespecificrecog-
nitionofneutralizingpathogenepitope,buttheydorequiresuﬃcientspecificityto
bindthepathogen. Giventhediﬃcultyinelicitingneutralizingantibodiesagainst
HIV, elicitation of non-neutralizing antibodies with strong Fc-mediated eﬀector
functionsisanappealinggoalforvaccinestrategies[2,61,212].
111.2.5 Fc-mediatedantibodyfunctions
Thebest-characterizedFc-mediatedfunctionsofIgGarecontrolledbyinteraction
with the membrane-bound Fc gamma receptors (FcγRs), which bind to the Fc
portionofIgGtoactivateorinhibitcells[159]. WithintheclassofFcγRs,thereare
five subtypes, each of which have diﬀerent cellular expression patterns and func-
tionsintheimmuneresponse[157]. Inparticular,FcγRIhashighaﬃnityforIgG1
and IgG3, and can mediate activation of the phagocytic cells that express it [1].
FcγRIIIA activatesNK cells [228], while FcγRIIA bindinginitiatesaninhibitory
signal to B cells and innate immune cells [206]. The remaining receptors have a
roleprimarilyinantibody-dependentcellularphagocytosis[157,158,206].
Antibod-dependentcellularcytotoxicity
Natural killer (NK) cells are important for eliminating bacteria- or virus-infected
cells to prevent the replication and release of new infectious agents. NK cells rec-
ognizeinfectedcellsthroughtwomainmechanisms[148]. Thefirstmechanismis
throughrecognitionofstressmarkersthatareexpressedonthesurfaceoninfected
cellsbyNKcellreceptors[51]. Thesecondmechanisminvolvesrecruitmentand
activationofNKcellsbyIgG-coatedtargetcellsthroughaprocessknownasanti-
body-dependentcellularcytotoxicity(ADCC)[46]. ADCCisinitiatedwhenanti-
gen-specific antibodies bind to the surface of an infected cell that is expressing
pathogen-specificproteinsandepitopesonitssurface[148]. Thecell-boundanti-
body recruits NK cells through interaction with NK-expressed FcγRIIIA and in-
ducesNKcellstoreleasecytotoxicmoleculesanddestroytheantibody-coatedtar-
12getcell[1,148].
This antibody function is important in HIV infection, given the its association
withslowerprogressiontoAIDS[66]andprotectionfrominfectionbysimianim-
munodeficiency virus (SIV) or the humanized form of SIV, SHIV, after vaccina-
tion or passive transfer [12, 75, 91]. Especially interesting is the observation that
ADCCwasasecondarycorrelateofprotectionintheonlyprotectiveHIVvaccine
trialtodate,RV144[30,80,104,182].
Antibody-dependentcellularphagocytosis
SimilartoADCCinitsmechanismofactivation,theprocessofantibody-dependent
cellularphagocytosis(ADCP)linksinnateimmunecelltoinfectedcells,ordirectly
topathogen, viaantibody. While ADCPis less clearlyregulated than ADCC,it is
at least partially controlled by interactions between the Fc region of the cell- or
pathogen-bound antibody and the FcRs of the phagocytic cell, including FcγRI,
IIA,andIIIB[1]. Phagocyticcells,whichincludemacrophages,monocytes,neu-
trophils, and eosinophils, express FcRs on their surface to recognize antibody-
coated cells or pathogens and initiate, phagocytosis, or cellular ingestion, of the
antibody-coated target [147]. Once inside the phagocyte, the pathogen or in-
fectedcellisdegradedinacidiccompartmentscalledphagosomes[5].
Complement-dependentcytotoxicity
Thecomplementsystemisacomponentoftheinnateimmunesystemthatconsists
of over thirty cell-associated and soluble factors [233, 234]. When activated, the
13complement system can lead to direct lysis of pathogens or infected cells. Com-
plementactivationcanoccurthroughthreemechanisms: theclassical,alternative,
andlectin-dependentpathways[1,148]. TheclassicalpathwayisactivatedbyIgG
or IgM mediated recruitment of the initiator molecule, C1q [77, 233]. Antigen-
boundIgGorIgMformsimmunecomplexes,whicharerecognizedbyC1qtogen-
erate the C1 molecular complex and initiate a cascade of complement molecule
deposition leading to lysis or phagocytosis of the infected cell or pathogen [77].
Theimportanceofcomplement-dependentcytotoxicityhasbeenwellestablished
in cancer therapeutics, where complement-recruiting activity is specifically engi-
neered into in vitro produced monoclonal antibodies directed against malignant
cells[151,152].
1.2.6 ProtectiveIgGinvaccination
Neutralization is the primary correlates of protection in most successful vaccines
to date [170], however, neutralizing antibodies have yet to be elicited in an HIV
vaccine. So while elicitation of a strong, and sustained, neutralizing antibody re-
sponseremainstheprimaryfocusoftheHIVvaccinefield,strategiestoelicitnon-
neutralizing antibodies with strong eﬀector functions are gaining wider attention
[2,61,212,220]. Inparticular,theonlymildlyprotectiveHIVvaccinetrialtodate,
RV144, failed to induce broadly neutralizing antibodies in vaccinees [103, 182],
however,secondarycorrelatesanalysisrevealedanassociationbetweenprotection
andADCCactivityinvaccinerecipients[30,80].
141.2.7 RegulationofFc-mediatedantibodyfunctions
ThequalityofFceﬀectorfunctionsiscontrolledthroughavarietyoffactors. Anti-
bodytiterisanimportantdeterminantoffunctionalactivitysinceantibodiesmust
presentinhighenoughconcentrationtoinitiatebindingtopathogensandgenerate
immune complexes to opsonize pathogens [82]. Isotype and subclass are crucial
for determining the strength and type of antibody functions [92], however, they
are rigid and diﬃcult to alter quickly since the determination of isotype and sub-
classaretheresultofirreversiblegeneticmodificationsthatoccurduringBcellac-
tivation [211]. In order to have finer control over antibody eﬀector functionality,
the immune system can modulate glycosylation of the Fc to quickly and specifi-
callytunetheFc-mediatedfunctionsoftheIgGmolecule[95,126,138,197].
1.3 N-linkedglycosylation
Glycosylation is the post-, or often co-, translational modification of proteins by
the addition of carbohydrate, accounting for the majority of all post-translation
modifications [189]. The addition of linear or highly branched chains of carbo-
hydrates,orglycans,topolypeptidesallowsforanexponentialincreaseinprotein
structural diversity and heterogeneity since the variation and complexity of po-
tential glycan structures are not limited by genomic sequence as amino acids are
[26].
N-linkedglycosylationreferstothespecificadditionofcarbohydrate,orglycan,
structures to an asparagine residue in an [Asn-X-Ser/Thr], or less commonly, an
15[Asn-X-Cys],motifwhereXcannotbeproline[210]. N-glycosylationisthemost
commonmodificationofsecretedandmembrane-boundproteinsandisoftenre-
quired for proper protein folding and function [144]. The pathway of N-glycan
synthesis and protein-attachment is an evolutionarily conserved process that is
shared among animals, plants and yeast [230]. However, some structural varia-
tionsincomplexN-glycansdoexistamongspecies,suggestingthatselectionpres-
surehasdriventheevolutionandmodificationofglycosylationindiﬀerentspecies
[229].
1.3.1 Nomenclatureandstructure
The building blocks of human N-linked glycans are individual sugar subunits in-
cluding N-Acetylglucosamine (GlcNAc), mannose (Man), glucose (Glc), galac-
tose (Gal), N-Acetylneuraminic acid (Neu5Ac), a type of sialic acid, and fucose
(Fuc) (See standard symbolic representations in Figure 1.2) [230]. These sugars
can be linked to each other in highly specific ways to create the glycan structures
commonlyfoundonglycoproteins[210].
Linkages of the sugars can occur in two major types, α and β, depending on
whether the linked subunits have the same or opposite stereochemistry (R or S),
respectively [26]. Linkages are made between specific carbons of each sugar, and
the specific linkage type is often indicatedwhen referringtostructures, for exam-
ple, Manβ1-4GlcNAc indicates a β linkage of carbon 1 of mannose with carbon
4 of GlcNAc. Proteins called glycosyltransferases (GTs) are highly specific en-
zymes that catalyze the addition of sugar nucleotides to acceptor substrates, of-
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ǉǏtenanexistingcarbohydratechain,inasugardonor/acceptorandlinkagespecific
manner [184]. For instance the enzyme β-1,4-mannosyl-glycoprotein 4-beta-N-
acetylglycosaminyltransferase,encodedbytheMGAT3gene,catalyzestheManβ1-
4GlcNAc linkage but cannot create a Manα1-6GlcNac linkage between the same
sugars.
1.3.2 N-glycosylationintheERandGolgi
N-glycosylation is a highly regulated and systematic process that begins while a
protein is being translated in the endoplasmic reticulum (ER), as shown in Fig-
ure 1.3 [231]. On the cytoplasmic face of the ER, a short carbohydrate chain is
synthesized starting with the transfer of a GlcNAc-phosphate (GlcNAc-P), from
nucleotide UDP-GlcNAc to the membrane-embedded dolichol phosphate (Dol-
P, . . 1 inFigure1.3)togenerateDol-P-P-GlcNAc[210]. Glycosyltransferasescat-
alyzethesequentialadditionofonemoreGlcNAcandfivemannosesubunits(from
GDP-Man)tocreateaMan5GlcNAc2-P-P-Dol( . . 2 inFigure1.3)structure,which
is flipped into the lumen of the ER by the flippase enzyme [210]. In the ER lu-
men, glycosyltransferases add an additional four mannose subunits, followed by
three glucose units (from UDP-Glc, transferred to the lumen as Glc-P-Dol) to
form Glc3Man9GlcNAc2-P-P-Dol ( . . 3 in Figure 1.3) [97]. This final structure is
transferred onto the glycoprotein by oligosaccharyltransferase (OST) through a
GlcNAc-β-Asn glycosidic bond [208]. Next, a series of trimming steps occur as
theproteintransitsthroughtheERandtheGolgi,beforefurtheradditionstogen-
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ǉǑerateacomplexN-glycanstructure[231].
TogenerateglycoproteinswithcomplexN-glycanstructures,theGlc3Man9Glc-
NAc2-P-P-Dol( . . 1 inFigure1.4)isattachedtotheproteinasitisbeingtranslated
into the ER [231]. Once translation is complete, the newly glycosylated protein
undergoesglycantrimmingintheER,losingallglucoseresiduesandonemannose
to become Man8GlcNAc2 ( . . 2 in Figure 1.4), which transits into the Cis-Golgi
[210]. These trimming steps are essential to induce proper folding of the pro-
tein, and recognition of incorrectly trimmed glycans will shunt the glycoprotein
to the proteasome for degradation [8, 144]. Addition and subsequent removal of
sugarsubunitsoccursbeforetheremovalofonemannoseandtheadditionofGlc-
NAc in the Medial-Golgi, creating a hybrid structure that has one arm containing
multiple mannose subunits and one arm with a complex structure ( . . 3 in Figure
1.4) [210]. To generate a fully complex structure, enzymes trim the two remain-
ingmannoseunitsandaddasecondGlcNAc,resultinginabiantennarystructure,
GlcNAc2Man3GlcNAc2 [210].
Onceitisinacomplexstructureform,theN-glycancanacquireadditionalsugar
subunits as it moves through the Medial-Golgi and encounters the GTs respon-
sible for modifying complex N-glycans [194]. In the Medial-Golgi, the fucosyl-
transferaseencodedbyFUT8mayaddacorefucose( . . 4 inFigure1.4)tothefirst
GlcNAcsubunit,thenastheglycoproteintransitsintotheTrans-Golgi,thegalac-
tosyltransferases encoded by B4GALT1, 2, or 3, can add galactoses to either arm
of the structure ( . . 5 in Figure 1.4) [231]. Once galactoses have been added, the
sialyltransferases encoded by ST6GAL1 or 2 can add Neu5Ac (sialic acids) ( . . 6
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ǊǉinFigure1.4)toeitherorbothgalactosesubunits[210]andtheMGAT3encoded
enzyme can add a bisecting GlcNAc . . 7 [230]. While all of these additions are
possible, regulation of the described GTs results in the generation of a staggering
variety of diﬀerent glycan structures, which are produced in a cell- and protein-
specificmanner[208].
1.4 IgGglycosylation
IgGs are glycosylated very specifically with an N-linked glycan at a single point
in their Fc region, which is essential for proper folding, and thermodynamic sta-
bility of the antibody (shown in yellow in Figure 1.1A) [31, 137]. While other
proteins can be glycosylated with a diverse array of diﬀerent sugar subunits, an-
tibody glycosylation relies on a mere four sugar subunits: fucose, galactose, N-
Acetylglucosamine (GlcNac), and N-Acetylneuraminic acid, a type of sialic acid
[90] The presence or absence of these sugar subunits on the IgG N-glycan (Fig-
ure 1.5) allows for the generation of 32 possible glycoforms [230]. Each of these
structuresimpartsslightlydiﬀerentinflammatoryandeﬀectorfunctionprofilesto
theattachedantibody,makingglycosylationanexquisitelypowerfulandsensitive
modificationforcontrollingthehumoralimmuneresponse[20,176].
1.4.1 Glycosylationoftherapeuticmonoclonalantibodies
Modification of IgG glycosylation is highly relevant for the generation of thera-
peutic monoclonal antibodies where techniques to modify and tune antibody ef-
fectorfunctionshavefocusedongeneticengineeringoftheglycosylationmachin-
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Ǌǋery [93, 238]. In particular tuning of IgG ADCC or CDC activity through mod-
ification of glycan structures is widely used in antibody therapeutics designed to
attack abnormal tumor cells, such as CD20 expressing B cells in non-Hodgkin’s
lymphoma[128]orHER2positivecellsinbreastcarcinoma[99,213].
The best characterized IgG glycan modification is that of the core fucose, the
absenceofwhichincreasestheADCCactivityofanantibodybyasmuchas50-fold
comparedtoafucosylatedantibody[153,168,201,203]. Thischangeinfunction
ismediatedbyanincreasedaﬃnityofFcγRIIIAforafucosylatedFcglycans[201]
due to steric hindrance of a fucose within the FcR’s Fc binding domain [62, 63,
141]. Thus,fucosyltransferase(FUT8)knockoutcelllinesarewidelyusedforthe
productionoftherapeuticmonoclonalantibodieswithoptimizedADCCactivity
againsttumorcells[129].
Bisecting GlcNac has also been observed to aﬀect ADCC activity in a fucose
independentmannerinvitro[122,225],alsomediatedbyaﬃnityforFcγRIII[55].
Additionally, a shorter, agalactosylated antibody has been associated with better
ADCCactivityinvitro[178].
In addition to ADCC recruitment, therapeutic antibodies have been designed
toeﬀectivelyrecruitcomplementdepositionandsubsequentcomplement-depen-
dentcytotoxicity(CDC)[130,181]. Theseeﬀectsaremostlyelicitedthroughthe
removal of galactose from the glycan, creating an agalactosylated antibody with a
strongaﬃnityforthemannose-bindinglectinofthecomplementpathway[127].
Thesecomplement-recruitingeﬀectsaremediatedinanFcRindependentmanner,
showingthediversityofFcN-glycanbindingtargets.
241.4.2 NaturalmodulationofIgGglycosylation
Studies of IgG glycosylation have focused primarily on engineering optimally ef-
fectivetherapeuticIgGs,however,glycosylationofIgGsinvivohasbeenwellchar-
acterized in autoimmune diseases, especially in rheumatoid arthritis (RA) [165],
systemiclupuserythematosus[219],andSjögren’ssyndrome[28]. EachIgGgly-
canhastwopossiblesitesforgalactosylation(Figure1.5),andthepresenceofone
(G1), two (G2), or no (G0) galactose units influences a variety of factors. An-
tibodies without galactose, IgG-G0, make up about 30% of a healthy individual’s
IgGs [172, 174]. However, during active RA, the proportion of IgG-G0 antibod-
ies increases with disease severity, with agalactosylated antibodies reaching up to
50% of the total IgG proportion [165, 166]. Interestingly, during disease remis-
sion, either after treatment or during pregnancy, a normal proportion of IgG-G0
isrestored[226,227]. Incontrast,thevariabilityofIgGgalactosylationovertime
inahealthyadultisaslowas5%[76],suggestingthatthechangesobservedduring
diseaseareduetoactivechangesinglycanprocessing.
InoppositiontotheinflammatoryagalactosylatedIgG,fullygalactosylatedan-
tibodies, IgG-G2, which make up about 20% of healthy IgGs [172], can mediate
compensatory inflammatory responses [195]. The presence of one or two termi-
nal sialic acids on the IgG glycan induces an active anti-inflammatory response
through their interaction with DC-SIGN [17]. This eﬀect of sialylated antibod-
ies make them potent initiators of anti-inflammatory cytokine cascades, which is
likelyanimportantfactorintheuseofpassivelytransferredintravenousimmuno-
globulin (IVIg) as treatment for autoimmune disorders [17, 27, 100] including
25chronicinflammatorydemyelinatingpolyneuropathy[214]andGuillain-Barresyn-
drome [65] as well as in the anti-rhesus D IgG treatment given to Rhesus factor
negativepregnantwomen[236].
Giventhepotentinvitroandinvivoeﬀectsoflowfucoseandhighb-GlcNAc,it
interestingtonotethataround90%ofahealthyindividual’sFcglycansarefucosy-
latedandbisectingGlcNAcoccursinasmallproportionofantibodies,aslowas10-
20%inhealthyadults[172],whichleavesasignificantmargininwhichtoincrease
eﬀectorfunctionalitynaturallybydecreasingfucoseorincreasingb-GlcNAccon-
tent. Since most antibodies are fucosylated or lack a b-GlcNAc, most circulating
antibodieshaveloweﬀectorfunctionality,whichmayhelppreventoveractivation
ofimmuneresponses.
1.5 RegulationofN-glycosylation
ControllingN-glycosylationisofcriticalimportanceforglycoproteinproduction
and function [230]. Many points in the production of complex N-glycans can
be regulated, and there are natural examples for each [210]. Limitation or ex-
pansion of the pool of nucleotide sugars that act as sugar donors can severely af-
fect the rate of addition of particular sugar subunits [118, 192, 194]. Addition-
ally, transcriptional regulation of GTs is known to alter the structure of produced
glycans, for instance down-regulation of the transcription of the galactosyltrans-
ferasegeneB4GALT1correlateswithdecreasedproductionofgalactosylatedpro-
teins in people with active rheumatoid arthritis [22, 107]. Perturbations to cel-
lular metabolism also induce significant changes in glycan patterns, in particular
26hypoxia-induced oxidative stress severely changes the structures found on IgGs
producedinvitro,whichmaybeduealteredkineticsofproteintransitthroughthe
ERandGolginetwork[114].
1.5.1 NaturalregulationofN-glycosylation
ExamplesofnaturalchangesinsystemicN-glycosylationshowhowlabileN-glyco-
sylationisduringspecificdiseasestatesaswellasinnaturalaging. Studiesofplasma
proteinglycosylationhaveobservedmodificationofproteinglycosylationinava-
rietyofcancersincludinggastric[111],ovarian[140,191],andthyroid[42]. Ad-
ditionally,inflammatorydiseasesareassociatedwithincreasedagalactosylatedgly-
coproteins, for example, during Alzheimer’s disease [124], after systemic inflam-
mation due to surgical intervention [162] and in people with high body mass in-
dexes[110,155]. Interestingassociationsbetweensexandagehavealsobeende-
scribed, with women decreasing their plasma protein fucosylation with age while
men’s increase [24, 110]. Additionally, enrichment of specific plasma glycopro-
teinN-glycanshasbeenassociatedwithfamiliallongevityinastudyofchildrenof
long-lived parents [54, 173, 190]. Taken together, these studies suggest that spe-
cific immunological signals that are induced during inflammatory disease states
mustbecapableofalteringglycanstructuresnaturally.
1.5.2 ArtificialmodulationofIgGN-glycosylation
InvestigationintotheartificialimmuneregulationofIgGhasfocusedonvaccina-
tion or in vitro stimulation of antibody-producing B cells. Studies in mice show
27that vaccination can alter IgG glycan structures, in particular, IgG fucosylation is
increased in mice immunized multiple times against OVA [78]. In humans, vac-
cination against flu or tetanus induces changes in vaccine-specific Fc glycosyla-
tionincludingincreasedsialylationanddecreasedbisectingGlcNac[200]. Invitro
studies of the regulation of IgG glycosylation show that specific immune signals
can alter IgG glycosylation in B cells, particularly galactosylation and sialylation.
[235],showingthatimmunesignalsarecapableofmakingspecificchangestothe
overallIgGglycan.
1.5.3 MechanismsofN-glycosylationregulation
While it is clear that IgG glycosylation is altered during inflammatory states, the
specificmechanismsthatcontrolglycosylationarehighlydiverse.
Geneticpolymorphisms
FunctionalgeneticmutationsinN-glycosylationmachineryareusuallylethal,but
those that are not often result in significant developmental retardation and im-
mune defects [68, 69], which is evidence of the importance of normal N-glyco-
sylationindevelopmentandimmunefunction. Theleastseverecongenitaldisor-
ders of glycosylation (CDG) can occur on a systemic level or a cell-type specific
mannerandhavebeenobservedtocauseavarietyofclinicalsymptomsincluding
neurological defects and immune defects caused by non-functional complement
systems[38].
28Transcriptional
The suggestion of epigenetic regulation of glycosylation has been postulated as a
mechanismforcontrollingtheincrediblycomplexandhighlyorderedpathwaysof
glycosylation[86,119,133],whichcouldexplainthesubstantialregulationofthis
un-templatedsystemofproteinmodification. Inparticular,fucosylationhasbeen
showntobeepigeneticallyregulatedinthecaseoftheglycosylationofthecytokine
TRAIL, in which methylation of the FUT4 gene shuts down fucose addition in
somecancercelllines[146].
A link between GT transcription and actual changes in N-glycosylation is im-
portantforanystudythatseekstouseglycosyltransferasetranscriptionasasurro-
gatemarkerofchangesinglycosylation. Fortunately,manystudieshavereporteda
linkbetweenGTtranscriptionandglycanchangesinavarietyofsystemsincluding
in studies of tissue-specific glycosylation [123, 149], alteration of IgG glycosyla-
tioninrheumatoidarthritis[22,108],andincellculturesystems[62,169].
Perturbationofmetabolism
WhiletranscriptionalregulationofGTsisapowerfulmechanismtomodifyglycan
structures, the N-glycosylation pathway is a complex network, and many factors
canbemodifiedtoaltertheresultingglycanstructure. Inparticular,perturbations
tothenucleotidesugarpoolsseverelylimitssugarsubunitadditionsifdonorsugars
are not being metabolized in suﬃcient quantity [230]. Additionally, localization
ofglycosylationenzymes,includingtransferasesandthecatabolizingglycosidehy-
drolases, is very important for the production of specific glycan structures [184],
29thus changes to the subcellular localization of any of the enzymes of the pathway
couldresultinalterationstofinalglycanstructure[231].
Alternationstocellularmetabolismcanalsoalterfunctionalglycosylation,pos-
sibly as a function of overall cellular changes or as a specifically regulated mecha-
nismtorespondstostress. Forinstance,inmonoclonalantibodyproductionsys-
tems,alterationofoxygenconcentrationandinductionofhypoxiastronglyaﬀects
IgG glycosylation [114]. Additionally, studies of HIV viral envelope production
haveobservedthattheenvglycansarerarelythecomplexN-glycanstructurespro-
ducedduringtransitthroughtheMedial-Golgi,butinsteadtheyarealmostexclu-
sively high mannose (Man5-9GlcNAc2) structures [58]. The cause of this diﬀer-
entialglycosylationisnotwellunderstood,butmaybecausedbyoverproduction
ofviralproteins,whichstresstheproteinproductionandglycosylationmachinery
causing proteins to skip over the glycosylation steps that occur in the later Golgi
compartments [231]. Interestingly, chemical intervention to reduce or increase
complex glycans on HIV env does not negatively impact envelope protein func-
tionorvirusinfectivity,showingthatthischangeisnotadvantageoustothevirus
and suggesting that high mannose glycosylation is not a virus-regulated process,
butageneralconsequenceofalteredproteinproductionandtranslationalmodifi-
cationininfectedcell[60].
1.6 Dissertationobjectives
Taken together, it is clear that IgG is a crucial component of an eﬀective immune
response,andinparticular,IgGsthathavestrongandspecificeﬀectorfunctionsare
30importantfordiseaseprotection. Literaturehighlightingarolefornon-neutralizing
antibodies in protection from HIV in vaccination [80], passive transfer [81], and
naturalviralcontrol[66],supportsthedevelopmentofavaccinestrategytoprefer-
entiallyinducenon-neutralizingantibodieswithstrongeﬀectorfunctionality. The
roleofIgGN-glycosylationinmediatingeﬀectivefunctionalresponsesisclear,so
understandinghowIgGglycosylationisregulatedisacrucialsteptowardharness-
ing this system in vaccination. The purpose of this study was to understand how
specific glycosylation is tuned naturally and how it can be altered using external
stimuli. To do this, we developed a novel Fc-specific IgG glycosylation analysis
techniquetoinvestigateIgGglycosylationchangesduringnaturalinfectionandin
response to HIV vaccination. We observed that bulk IgG glycosylation is altered
during HIV infection and the modification to IgG glycan is associated with the
productionofinflammatorycytokines,includingIP10andC-reactiveprotein,sug-
gesting a role for systemic inflammatory signaling in driving modification of IgG
glycosylation. Additionally,weobservedthatglycosylationofantigen-specifican-
tibodiesdiﬀersamongdiﬀerentantigens,suggestingthatglycosylationisalsoreg-
ulatedattheantigen-specificcelllevel. Recognizingthatglycosylationisregulated
byimmunesignals,wecharacterizedsomeofthespecificsignalsthatalterGTex-
pressioninprimaryBcellsexvivoandfoundthatparticulartoll-likereceptorago-
nistscanaltertheGTexpressionprofilesandputativeglycanprofilesofstimulated
cells. Theresultsofthisstudyshowthatnotonlyisglycosylationregulated,itcan
bespecificallyelicitedthroughvaccinationusingspecificimmunesignals.
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HighthroughputanalysisofIgGFc
glycosylationbycapillaryelectrophoresis
TheN-glycanoftheIgGconstantregion(Fc)playsacentralroleintuning
and directing multiple antibody functions in vivo, including antibody-dependent
cellularcytotoxicity,complementdeposition,andtheregulationofinflammation.
However, traditional methods of N-glycan analysis, including HPLC and mass
spectrometry are technically challenging and ill-suited to handle large numbersof low concentration samples needed for the analysis of the N-glycans on poly-
clonal IgG derived from clinical or animal sources. Here we describe a capillary
electrophoresis-basedtechniquetoanalyzeplasma-derivedpolyclonalIgG-glyco-
sylationquicklyandaccuratelyinacost-eﬀective,sensitivemannerwellsuitedfor
high-throughputanalyses. Additionally,becauseasignificantfractionofpolyclonal
IgGisglycosylatedonbothFcandFabdomains,wedescribedomain-specificgly-
cosylation analysis of polyclonal human, rhesus and mouse IgGs. This approach
allows for the rapid, accurate, and sensitive analysis of Fc-specific IgG glycosyla-
tion, critical for population-level studies of how antibody glycosylation varies in
response to vaccination or infection, and across disease states ranging from au-
toimmunitytocancerinbothclinicalandanimalstudies.
2.1 Background
Beyond their ability to neutralize pathogens, antibodies can mediate an array of
eﬀectorfunctionsthroughtheirinteractionwithFc-receptors,andrecruitmentof
complement molecules and mammalian lectin-like molecules [102]. While the
neutralizing activity of an antibody is mediated primarily by its variable domain
(Fab,antigen-bindingfragment),itsabilitytoperformextra-neutralizingfunctions
isdeterminedbytheconstantdomain(Fc,crystallizablefragment)[197]. Though
the Fc is referred to as constant, it is, in fact, variable in two major aspects: a)
protein sequence varies through subclass or isotype selection [160] and b) post-
translationalmodificationofN-glycosylationthatcanoccurrapidlyduringanim-
munologic response [241]. Together, these alterations in the antibody Fc signifi-
33cantlymodifytheeﬀectorfunctionofantibodies,suchasantibody-dependentcel-
lularcytotoxicity(ADCC)[55,201,203,205]andcomplement-dependentcyto-
toxicity(CDC)[105]. Whilehigh-throughputmethodsareavailabletoprofilethe
isotype/subclass selection profile of polyclonal antibody pools [33], comparable
methodsforeﬃcientanalysisofglycanprofilesarenotavailable.
Studies of therapeutic monoclonal antibodies have clearly demonstrated the
criticalnatureoftheantibodyglycan: monoclonaltherapeuticantibodiesthatlack
fucose[201,203,205]orcontainabisectingN-Acetylglucosamine(GlcNAc)[55]
have significantly higher ADCC activity. In addition to their role in determining
eﬀectorfunction,inflammatoryresponsesaredramaticallymodulatedbyFcglyco-
sylation. Inparticular,theadditionofterminalsialicacidstotheFcglycanresults
intheinductionofapotentanti-inflammatoryresponse[16,27]. Moreover,pop-
ulation level studies have shown that IgG glycosylation varies significantly with
age, pregnancy, and during autoimmune-disease flares [42, 106, 164, 227]. More
recentstudiesidentifyantigen-specificantibodyglycanalterations,suggestingthat
IgG-glycosylationisdeterminedatthelevelofindividualBcells[4,49,200,242].
Given the significant impact of N-glycosylation on programming antibody func-
tion, high-resolution analyses of polyclonal humoral immune responses will de-
pend on the ability to profile the N-linked glycan in addition to antibody sub-
class and isotype. However, studies of IgG-glycosylation in vivo have been his-
torically limited by the low-throughput nature of existing analytical techniques,
which additionally tend to require prohibitively expensive instrumentation and
large quantities of sample, limiting the scope of research into natural regulation
34of IgG-glycosylation. However, the known importance of this post-translational
modification motivates the development of new tools to enable investigation of
IgG-glycanselicitedthroughvaccinationandinnaturalinfection,bothonthelevel
oftotalplasmaIgGandamongantigen-specificantibodies.
Traditional approaches to analyzing IgG N-glycosylation have relied primar-
ily on high-performance liquid chromatography (HPLC) or mass spectrometry
(MS), both of which require relatively large quantities of antibody for accurate
analysis as well as significant time and expertise to acquire and analyze data [90].
While MS oﬀers remarkable structural resolution of N-glycans, it is poorly quan-
titative,ontheotherhand,whileHPLCishighlyquantitative,itisexpensive,and
bothmethodsaredistinctlylowthroughput. AsstudiesofIgGglycosylationbegin
tofocus on in vivo modifications, both in human populationsand animalmodels,
thesamplequantityavailabledecreasesasthenumberofsamplesincreases. Thus,
aclearneedexistsforthedevelopmentofasimpletechniquethatcombinessensi-
tivequantitationwithhigh-throughputcapacity.
Capillary electrophoresis (CE) oﬀers a unique high-throughput, quantitative
analytical tool for the analysis of antibody glycosylation. Specifically, the use of
conventional DNA sequencing equipment to perform glycan structure analysis
bycapillaryelectrophoresisisanexcellentalternativetotheestablishedmethods,
with advantages in simplicity, ease, throughput, structural resolution, and sensi-
tivity [39, 89, 116, 183]. Previously described CE techniques for antibody gly-
can analysis have focused on the analysis of whole IgG, as the large majority of
monoclonal antibodies lack Fab glycan-sites [185]. However, as many as 30%
35of serum-derived Fab fragments contain an N-glycosylation motif, and Fab gly-
cansdiﬀersignificantlyfromthosetypicallyfoundontheFc-domain,inparticular,
FabN-glycanscontainincreasedsialicacidanddecreasedfucosecontent[18,84,
136]. Thus, studies interrogating polyclonal antibody glycosylation aimed at un-
derstandingthefunctionalsignificanceoftheseregulatedpost-translationalmod-
ificationswilldependontheabilitytoresolveFcandFabglycansseparately.
Here we describe a high-throughput, inexpensive, sensitive, and accurate ap-
proach for IgG N-glycan analysis of polyclonal antibodies. This methodology al-
lows for separate analysis of the N-glycans from whole IgG, Fc, or Fab domains
using capillary electrophoresis performed on a DNA-sequencer, providing an ac-
curate, quantitative, and relatively inexpensive and simple tool to probe IgG gly-
cosylation,evenwhensamplequantitiesarelimited. Thistechniquewillbeuseful
for the analysis of antibody glycan variation following vaccination, in natural in-
fection, as well as in non-infectious pathological conditions both in humans and
animalmodels,facilitatingourunderstandingoftheimmunologicalimpactofthe
abilityofaBcelltotuneantibodyactivityviavariantglycosylation.  
2.2 Methods
Samples
Optimizationofdigestionandseparationconditionswasperformedoncommer-
cially available, pooled IgG from healthy donors (Sigma Aldrich, human IgG and
mouseIgG)orapoolofIgGspurifiedfromhealthyrhesusmonkeys(Non-Human
36PrimateReagentResource). HealthyhumansubjectswererecruitedthroughBrig-
hamandWomen’sHospitalPhenoGeneticProject. TheInstitutionalReviewBoard
ofPartnersHealthcareapprovedthestudy,andeachsubjectgavewritteninformed
consent. Rhesusmacaqueplasmawasobtainedfromhealthy,non-immunizedan-
imals, provided by D. Barouch. All studies involving rhesus monkeys were ap-
proved by the Harvard Medical School Institutional Animal Care and Use Com-
mittee (IACUC). Plasma from C57Bl/6 mice was purchased from the Jackson
Laboratory(BarHarbor,Maine).
IsolationofIgG
HumanandrhesusplasmawascollectedfromfreshblooddrawninACDtubesby
centrifugationandfrozenat-80◦C.IgGsfromhumanandrhesuswereisolatedus-
ingMelon Gel IgG purification resin (Thermo Fisher) according tothe manufac-
turer’sinstructions. MouseIgGwasisolatedusingproteinA/Gcolumns(Thermo
Fisher) and eluted in 0.1 M citrate buﬀer pH 2.9, and subsequently neutralized
in potassium 0.1 M phosphate buﬀer pH 8.9. All IgGs were purified and stored
inbuﬀerswithoutprimaryamines,toavoidproblemswithdownstreamglycanla-
beling. IgG concentrations were determined by measuring A280on a Nanodrop
spectrophotometer.
RemovalofN-glycanfromprotein
Once IgG was purified, glycans were released from protein using enzymatic di-
gestion with Peptide-N-Glycosidase F (PNGaseF, New England Biolabs). Pro-
37tein was denatured using 2 μl of the provided denaturation buﬀer and incubated
at95◦Cfor10minutes. Sampleswerecooledon icebeforethe additionof4 μlof
G7 digestion buﬀer provided by the manufacturer, 4 μl of 10% NP-40, 375 Units
ofPNGaseFandwatertoatotalvolumeof40μl. Reactionmixturewasincubated
at37◦Cfor30minutes. Twohundredmicrolitersofice-coldethanolwasaddedto
eachwelltoprecipitateproteinandseparatereleaseglycans. Plateswereincubated
fortenminutesat-20◦Candprecipitatedproteinwaspelletedbycentrifugationat
2700xgfortenminutes. Glycancontainingsupernatantsweretransferredtofresh
platesanddriedcompletelyinaLabconcocentrivap. Driedglycanscanbestored
at-20◦Cindefinitely.
Labelingandcleanupoffreeglycan
Thoroughly dried glycans were labeled by reductive amination using 2 μl of a 1:1
mixture of 25 mM 8-aminopyrene-1,3,6-trisulfonic acid, APTS (Life Technolo-
gies)in1.2Mcitricacidand1Msodium-cyanoborohydrideinTHF(SigmaAld-
rich). Plates were sealed tightly, and the reduction reaction proceeded protected
fromlightat55◦Cfor3hours. Unreacteddyewasremovedusingfreshsize-exclu-
sion columns, prepared by pipetting 250 μl of 50% P2 gel slurry (Bio-Rad) to the
wellsofa96wellemptyfilterplate(HarvardApparatus),packedbycentrifugation
at 750 x g for 1 minute and washed with 100 μl of ultrapure water. Fluorescently
labeledglycanswereresuspendedin60μofultrapurewaterandapplieddirectlyto
thetopofthepackedsize-exclusioncolumnsinthefilterplate. Thesewerespunat
750xgfor2minutes,releasinglabeledglycansintheflow-through. Glycanswere
38storedat4◦CuntilanalysisonaDNAsequencer.
Electrophoreticseparationandanalysisofglycan
Samples were transferred into a PCR plate, diluted 1:10 in ultrapure water, and
loaded onto a 3130XL ABI DNA sequencer. Parameters for run are as described
[116] using POP7 polymer in a 36 cm capillary. Acquisition software was set to
exportdataas.fsafiles.
Datafileswereexportedfromacquisitionsoftwareas.fsa,whichwereconverted
to .xml using conversion software provided by Applied Biosystems. Converted
fileswereanalyzedusingMATLAB(TheMathWorks,Inc)toalignpeaksandcal-
culatetheareaunderthecurveforeachpeakusingacustomdesignedscript.
Glycanpeakidentification
Individual fluorescently labeled glycans pass through the acrylamide matrix at a
rate dependent on both the size and charge of the glycan. The APTS dye pro-
videschargetoallthemoleculestoallowforelectrophoreticmigration. Sialylated
speciescontainadditionalchargedependingonthenumberofsialicacidsandthus
travelfastestthroughthematrix. Toidentifypeaks,includinghighmannosestruc-
tures, known glycan standards (Prozyme) were labeled with APTS as described
for IgG glycans and spiked into human IgG-derived samples. Prozyme standards
andIgG-derivedglycansweredigestedwithexoglycosidases(NEB)todetermine
additionalstructures,seeTable2.1.
For clarity in reporting results, the 21 individual structures that we observe by
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ǌǍCE are categorized into six major groups: agalactosylated (G0), monogalactosy-
lated (G1), digalactosylated (G2), fucosylated (F), bisected (B), and sialylated
(S),asdescribedinTable2.2.
HPLCanalysisofIgGglycan
IgG samples were separated by SDS PAGE on 4-12% Bis-Tris gels (Life Tech-
nologies, UK) and stained with Coomassie blue stain for 30 minutes. Gel bands
were excised and alternately washed with 100% Acetonitrile and ultrapure water
until the gel bands were suﬃciently dehydrated. Dried gel bands were incubated
overnightat37◦Cwith100U/mlofPNgaseF(NewEnglandBiolabs,UK)in30μl
distilledwater. Thefollowingday,freeglycanswereelutedbyserialwashingofgel
slices with distilled water. Eluted glycans were dried down in a centrifugal evap-
orator (Vacufuge plus, Eppendorf, Germany) and labeled with 2-aminobenzoic
acid (2-AA) using the Ludger 2-AA labeling kit and clean up cartridges (Ludger,
Culham,UK).
Normal phase high-performance liquid chromatography was used to separate
and analyze the 2-AA labeled N-glycans. Samples were injected into a Ludger
amide HPLC column (150 mm length and 4.6 mm internal diameter) on an Al-
lianceWaters2695separationmodulefittedwithaWaters2475multi-wavelength
fluorescence detector (λex 330nm and λem 420nm). The solvent gradient started
with35%AmmoniumFormate(50mM,pH4.4)and65%Acetonitrileat1ml/min
andwasgraduallyincreasedto100%AmmoniumFormateover22.5minutesand
thensubsequentlygraduallydecreasedbackto35%AmmoniumFormateoverthe
46Table 2.2: Major categories of glycan structures. Individual glycan structures are
categorized based on their galactose, fucose, bisecting GlcNAc, or sialic acid content as
described. NumbersindicatepeakassignmentasidentifiedinTable2.1andFigure2.1.
Category SpecificPeaks(PeaknumberfromTable1)
Agalactosylated(G0) G0(8b),G0B(9),G0F(10),G0FB(12)
Monogalactosylated(G1) G1 (11 & 11.5), G1F (13 & 14), G1B (12.5),
G1BF(15),G1S1(4.5),G1S1F(5),G1S1B(ND),
G1S1FB(ND)
Digalactosylated(G2) G2 (15), G2F (16), G2B (15.5), G2FB (17),
G2S1(6),G2S1F(8a),G2S1B(7),G2S1FB(ND),
G2S2(1),G2S2F(3),G2S2B(2),G2S2FB(4)
Fucosylated G0F(10),G0FB(12),G1F(13&14),G1FB(15),
G1S1F(5),G1S1FB(ND),G2F(16),G2FB(17),
G2S1F (8a), G2S1FB (ND), G2S2F (3), G2S2FB
(4)
Bisected G0B(9),G0FB(12),G1B(12.5),G1FB(15),G2B
(15.5), G2FB (17), G1S1B (ND), G1S1FB (ND),
G2S1B (7), G2S1FB (ND), G2S2B (2), G2S2FB
(4)
SialicAcid G1S1 (4.5), G1S1F (5), G1S1B (ND), G1S1FB
(ND),G2S1(6),G2S1F(8a),G2S1B(7),G2S1FB
(ND), G2S2 (1), G2S2F (3), G2S2B (2), G2S2FB
(4)
47next7.5minutes. Peakassignmentswereconfirmedbycomparisonwithstandards
(Ludger2AAlabeledIgGGlycanlibrary)andalsowithpreviousmassspectromet-
ricprofilesofIgGglycans.
DigestionofIgGintoFabandFcfragments
PurifiedhumanandrhesusIgGweredigestedintoFcandF(ab’)2 fragmentsusing
IdeS, Immunoglobulin G degrading enzyme of S. pyogenes (Genovis, Sweden).
TwentymicrogramsofpurifiedhumanIgG,ataconcentrationof1mg/mlinPBS,
was digested with two-fold serial dilutions of between 0.625 and 40 Units of en-
zymefor1hourat37◦C.RhesusIgGrequired18hoursincubationat37◦Ctofully
digest the same amount of IgG. Because mouse IgG is resistant to IdeS cleavage,
thestreptococcalcysteineproteaseSpeB(Genovis,Sweden)wasusedtodegrade
thesampleintoFd(digestedfragmentcontainingthevariableregionoftheheavy
chain) and Fc fragments. Twenty micrograms of murine IgG was digested with
two-folddilutionsofSpeBbetween0.625and10Unitsin1
Analysis of IgG fragmentation and separation was performed using precast 4-
12%Bis-Trisgradientgels(LifeTechnologies). Proteinwasloadedat5μgperlane
alongside a prestained ladder and bands were visualized using Coomassie. Band
intensity was quantified using GelQuant.NET software provided by biochemlab-
solutions.com.
48SeparationofFcandFabfragments
To separate the digested fragments, protein A or G coated magnetic beads (Mil-
lipore) were used to bind and enrich the Fc portions. In a 96 well PCR plate, 1,
5, 10, 15, 20, or 30 μl of protein A or G beads were added to each well. Beads
werewashedtwicewith200 μlPBS,usinga96wellmagneticplatetoimmobilize
beads (SPRIPlate Beckman Coulter). Digested IgG was diluted in 80 μl of PBS,
andtheentirevolumewastransferredtotheplatecontainingwashedbeads. Plates
were sealed tightly and incubated at room temperature with vortexing for 1 hour.
Plateswerespundownandsetintothemagnetforfiveminutestoseparatebeads.
F(ab’)2 andFabfragments,whichbindpoorlytoproteinAandG,remainedinthe
supernatant,alongwithIdeSorSpeB,whichcontainnoN-glycosylationsitesand
thusdoesnotinterferewithglycananalysis. Thesupernatantfractionwasremoved
anddriedtoapproximately18 μlinaLabconcoCentivaptoconcentrateFabpro-
tein. The bead-bound fraction contained Fc and any incompletely digested IgG.
The beads were washed twice in 200 μl of PBS and brought up in 18 μl of PBS or
water. NeitherproteinA/GnorthemagneticbeadscontainanyN-linkedglycans,
soglycanreleasecanoccurwithoutremovingbeads.
492.3 Results
2.3.1 Analysisofglycansbycapillaryelectrophoresisishighlysen-
sitiveandreproducible
To test our glycan analysis technique, IgG glycans were enzymatically released,
purified, fluorescently labeled and electrophoretically separated on the DNA se-
quencer as described. Individual peaks on the CE spectrum, as shown in Figure
2.1A,wereidentifiedusingstandardsandexoglycosidasedigestionasdescribedin
Table2.1. Individualglycanstructureswerebroadlyclassifiedintocategoriesasde-
scribedinTable2.2. Thesecategoriesgiveabroaddescriptionoftheinflammatory
profile (galactosylation and sialylation) and the eﬀector functionality (fucosyla-
tion and bisected-GlcNAc-containing) profile of the polyclonal IgG population,
providingasimplifiedandmoreeasilyinterpretedsnapshotoftheglyco-profileof
eachsample.
Next,wesoughttoestablishthelevelofsensitivityofthisanalyticplatform. Us-
ingtheCEtechniquedescribed, startingat50 μgtwo-foldserialdilutionsoftotal
humanIgGwereanalyzedaswholeIgG,Fc,andFab. Weobservedthatreliablesig-
nals could be collected for several categories of glycan structures using as little as
3.125 μgofstartingwholeIgG(Figure2.1B),aquantitypresentinapproximately
1 μl of plasma. Moreover, analysis of neutral (asialylated) glycans was more sen-
sitive, with robust signals over background detected using as little as 0.73 μg of
IgG (Figure 2.1C), equivalent to less than 0.1 μl of plasma. The lower sensitivity
forsialylatedglycandetectionlikelyresultsfromthepositionofsialylatedspecies’
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Ǎǉelution,whichisneartheelutionpointofunreacteddye,thusincreasingthenoise
tosignalratio.
Toassessthevariationandreproducibilityandusefulnessofthistechnique,two
independent experiments were performed: a) one sample was prepared and run
twentyindependenttimestomeasurereproducibility, andb)twenty purifiedim-
munoglobulin samples from diﬀerent healthy human donors were run at once to
quantifythelevelofvariationwithinapopulationsampleset(Figure2.2A).Crit-
ically, the coeﬃcient of variation [(Standard deviation of all runs / Average of all
runs) x 100%] calculated for a) was below 8% for each structure (Figure 2.2B in
black), demonstrating robust reproducibility. In contrast, the average variation
from the mean among samples from diﬀerent subjects ranged from 30 and 70%,
withsomestructuresbeinghighlyvariable,includingbisectingGlcNAc-containing,
agalactosylatedandsialylatedstructures(Figure2.2Bingray). Thisresultdemon-
strates the feasibility of accurately detecting variation within populations as well
aschangeswithinanindividualovertime.
2.3.2 CapillaryelectrophoresisiscomparabletoHPLC
Traditionally, glycan analysis is performed using MS or HPLC. These techniques
benefitfromdecadesofstandardizationandareconsideredgold-standardsforgly-
can analysis. While ultra-performance liquid chromatography can use very small
volumesofsample,eachruntakesapproximatelytwohours. Thus,theadvantages
of capillary electrophoresis for antibody glycan analysis include lower cost, ease
of use, increased sensitivity, and most critically, increased speed of data output.
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Figure2.2: Capillaryelectrophoresisishighlyreproducible. A: Total proportions
of glycan structure categories, as described in Table 2.2, are represented for one sample
preparedandanalyzed20times,blacklines,and20diﬀerentsamplesanalyzedtogether,
graylines. B:Percentvariationoftherepeatedanalyzesisexpressedforthesinglesam-
ple,inblack,andthemultiplesamples,ingray.
53Therefore,wesoughttodeterminetheaccuracyofCEcomparedtoHPLC.When
we compared the samples run by HPLC versus CE (Figure 2.3), we observed ex-
cellent concordance between the techniques for every structure category except
b-GlcNAc. Importantly, nearly all structures were significantly correlated though
some discrepancy was observed in the absolute numbers of the structures calcu-
lated, likely due to the diﬀerences in sample preparation and labeling chemistry.
Diﬀerencesinb-GlcNAcinparticularmaycomefromdiﬀerencesintheabilityof
each technique to resolve specific structures. Overall, these results clearly illus-
trate that changes in glycosylation that are measurable by HPLC can be reliably
capturedbyCE.
2.3.3 FcandFabarereliablyseparatedbyIdeSdigestion
BetweentenandthirtypercentofserumpolyclonalantibodiesexhibitFabglyco-
sylation, which diﬀer significantly from that of Fc, though only Fc domain glyco-
sylationisknowntodirectlyimpacteﬀectorfunction[178]. Thus,reliablesepara-
tionoftheFcandFabfragmentsofanantibodyiscriticalforthecharacterizationof
the Fc-glycan modifications that determine antibody functionality. Therefore, to
limitthecontributionofFab-associatedglycanstotheoverallglycansignal,wede-
veloped a high-throughput, 96 well-plate-based method to separate IgG Fc from
Fab domains. For human samples, digestion with 5 Units of IdeS is suﬃcient to
separate90%oftheIgGintoFcandF(ab’)2 (Figure2.4A).Incontrast,40Unitsof
IdeSwererequiredforthedigestionofrhesusIgGtoachieve99%digestion(Figure
2.41B).Finally,todigestmurineIgG,10UnitsofSpeBenzymewasusedtodigest
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Ǎǎ92% of the IgG into Fc, Fd (digested fragment of the heavy chain containing the
variableregion)andlightchainfragments(Figure2.4C).
Next, protein A or G was used to isolate the Fc fractions from the cleaved Fab
portionoftheantibody. ForhumanIgG,5 μlofmagneticproteinGbeads,which
bindtoallfoursubclassesofIgG,wassuﬃcienttorecoverthemaximumof80%of
totalFcwhile90%oftheF(ab)2 remainedintheunboundfraction(Figure2.4D).
Forrhesus,proteinGexhibitedlowerbindingofIgG,60%oftheFcwasrecovered
on20μlofbeads,whichcontainedlessthan10%ofcontaminatingF(ab)2 (Figure
2.4E). Finally, for murine IgG, protein A beads were used to maximize eﬃciency,
30μlofbeadswassuitabletoisolate60%oftotalFcwithnocontaminatingFabor
wholeIgG(Figure2.4F).
2.3.4 IgGFcandFabhavedifferentglycosylationprofiles
Unlike monoclonal antibodies, as many as 20-30% of total Fab fragments are gly-
cosylatedinanaturallyproduced,polyclonalmixtureofantibodies[185]. Todate,
modulation of Fab glycosylation in vivo has been largely overlooked, likely due to
thecumbersomenatureoftheexistinganalysistechniques,sotheroleofFabglyco-
sylationinantibodyfunctionispoorlyunderstood. However,itisknownthatFab
domain-attached glycans have diﬀerent structures, in particular they are consis-
tentlymoresialylatedandlessfucosylatedthanthoseontheFcdomain[18]. Thus,
studiestoprofileglycan-mediatedchangesknowntoimpactFc-functionmustfo-
cus specifically on the Fc-glycan, rather than that of the intact antibody, as can be
achievedbyseparatingtheFcandFabportionssothattheycanbeeasilyanalyzed
57inparallel.
Analysis of each domain confirmed the significant disparity in sialylation and
fucosylationoftheglycanstructuresattachedtoeachportionoftheantibody(Fig-
ure 2.5A). Additionally, we observeddiﬀerences in all structurecategories except
bisectingGlcNAc-containingstructures,whichwerenotsignificantlydiﬀerentbe-
tween Fc and Fab fragments (Figure 2.5A). Given the importance of fucose con-
tent in driving ADCC activity [161, 163], the decreased proportion of fucosyla-
tionintheFabfragmentshasthepotentialtosignificantlyskewtheinterpretation
of the functional capacity of a given antibody population if intact IgG glycans are
analyzed. As would be expected, whole antibody consistently exhibited a glyco-
sylation profile that was intermediate between the Fc and Fab profiles, showing
that analysis of intact IgG likely obscures variation of both Fc and Fab glycosyla-
tion. While many MS and HPLC techniques are performed on glycans released
from the heavy chain of the antibody to eliminate the light chain variable region-
derivedglycans,theinclusionofheavychainvariabledomain-derivedFabglycans
remainsalimitationtospecificassessmentofthenatureofFc-glycanmodulation.
Thus,proteolytic-basedseparationandanalysisoftheIgGfragmentsisamorere-
liabletechniqueforanalyzingfragmentspecificglycosylation.
TodeterminethesensitivityofdetectionfortheseparateIgGfragments,weper-
formed two-fold serial dilutions of intact IgG, starting at 50 μg, then fragmented
and fractionated antibody before glycan release, separation, and analysis. By sep-
arating Fc from Fab, we observed a decrease in sialylation allowing for sensitivity
of as little as 0.73 μg of starting IgG (Figure 2.5B), Conversely, Fab analysis was
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ǍǑlesssensitive,requiringatleast6.25μgofIgG(Figure2.5C),likelyduetothehigh
proportionofsialicacidcontainingglycans.
2.3.5 IgGglycanprofilesdifferamonghumans,rhesusandmice
Experimental animal models, including rodents and non-human primates, play a
critical role in the study and development of antibody and immunomodulatory
therapeuticsandvaccinesagainstmanydiseasesandinfectiouspathogens. Specifi-
cally,thenon-humanprimatemodelofHIV,simianimmunodeficiency(SIV),has
playedacentralroleinadvancingourunderstandingofthecorrelatesofprotection
from infection following vaccination, as well as understanding the protective role
of non-neutralizing antibody activities in vivo [21, 75, 81]. Thus, the application
of CE-based Fc-glycan profiling to samples from non-human animal models may
accelerate our understanding of the role and regulation of Fc-eﬀector functions
mediatedbyglycosylation.
Accordingly,wemodifiedormethodsforhumanglycananalysisforevaluation
of rhesus IgG by using 40 Units of IdeS in an overnight digestion, followed by
Fc separation using 30 μl of protein G beads. To isolate murine Fc, we used 10
UnitsofSpeBenzyme,asdescribedinthemethodssection,and30μlofProteinA
beads to separate the Fc from Fd and light chain fragments. These adaptations al-
lowedustoanalyzewhole,FcandFabportionsofhuman,rhesusandmouseIgGs.
Whileallthreespecieshaveanattachedcomplexbiantennaryglycanstructure,the
proportions of each particular structure vary significantly [6, 179]. Interestingly,
whilerhesusandmiceattachasialicacidmoleculeknownasN-Glyconeuraminic
60acid(NGNA),humansattachN-Acetylneuraminicacid(NANA)duetoagenetic
deletionoftheNGNAproducingenzymeoveronemillionyearsago[13,44,72].
However, this molecular diﬀerence does not impact our analysis since the two
sialicacidsbehavesimilarlyintheirimpactonglycanmigration. Weobservedspe-
cific diﬀerences in the glycans from all three species. In particular, mice have sig-
nificantly greater sialylation and lower agalactosylation than humans and rhesus
(Figure 2.6). Additionally, mice appear to have lower fucosylation than primates.
Finally, rhesus IgGs have more bisected Fc glycans, driven by an overall greater
varianceamonganimals[6,179].
Observationofthesediﬀerencesamongmammalssuggestsastrongevolution-
ary pressure to diversify IgG glycosylation, perhaps in response to pressure from
infectious agents. Use of this technique in experimental animal models may al-
low for both understanding of the impact of variant IgG glycosylation on immu-
nity,butidentificationofmechanismswherebyantibodyFc-glycosylationmaybe
tuned and ultimately rationally modified to drive production of functionally op-
timized antibodies. Collectively, the ability to apply Fc-targeted CE-based glycan
analysistodiverseanimalspeciesreflectstheversatilityofthistechniqueandmay
aidintheclinicaltranslationofstudiesperformedinanimalmodels.
2.4 Discussion
Withgrowingappreciationoftheroleofantibodyglycosylationintuningantibody
eﬀector function, an analytical technique capable of analyzing the glycosylation
profiles of large numbers of serum-derived, polyclonal antibodies is needed. Ul-
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ǎǊtimately, an analytical tool aimed at characterizing antibody glycosylation in vivo
must(a)havea high-throughputcapacity, (b)exhibit robustreliability andsensi-
tivity for Fc-specific glycan analysis in multiple species, (c) be cost-eﬀective, and
(d) be easy to implement in laboratories globally, requiring minimal specialized
analytical staﬀ. Here we present such a high-throughput, low-cost technique that
additionallyallowsforrapidanalysisanddemonstrateitsapplicationtointactIgG,
Fc,andFabacrossmultiplespecies.
IncomparisontoHPLC,whichtakesaslongasanhourtorunasinglesample,
an ABI 3500 can analyze 24 samples simultaneously in the span of approximately
15 minutes, with the ability to load two 96 well plates simultaneously, thus en-
abling the processing of as many as one thousand samples in a day. In addition
to its remarkable throughput, this approach demonstrates robust sensitivity, per-
mitting full glycan analysis with small quantities of high-value samples, requiring
as little as 1 μl of plasma. This high-throughput, sample-sparing technology is of
particularimportanceintheclinicalevaluationofvaccinetrialsthatseektoprofile
the functional potential of vaccine-induced humoral immune responses in large
populations.
Importantly,thecostofthisassayissignificantlylowerthanHPLCorMS.This
cost-eﬀectiveness is linked to a reduction in equipment and labor costs. Unlike
HPLCorMS,whichrequirespecializedequipmentandspeciallytrainedstaﬀ,any
lab with access to a DNA sequencer can perform this assay. Core facility equip-
mentissuﬃcient,astheprotocoldoesnotrequirepermanentmodificationstothe
sequencerandglycananalysiscanberunalongsideDNAsampleswithease. More-
63over,dataanalysisisuser-friendlyandcanbedoneusinganypeak-areacalculating
software,includingImageJorcustomizedMATLABscripts,allowingwidespread
adoption. At a cost of less than 5USD for labeling and running each sample, and
withthepossibilityforfurthercost-reductionswithprocessautomation,thistech-
niqueallowsforsignificantscaleup. Altogether,thetechniquecanbeusedtoana-
lyzethousandsofsamplesinlongitudinalorcross-sectionalstudies,increasingthe
powertofindmeaningfulresultsinlargestudies.
Since most studies of infection and vaccination begin in non-human animal
studies,itiscriticalthatatooltoassessantibodycharacteristicsisapplicableacross
species. Someimportantrelationshipsbetweenglycanstructureandeﬀectorfunc-
tionarewellconservedamongmammals[198]andIgGglycovariationmayprove
tobeanimportantendpointmeasureforvaccineeﬃcacy. Thetechniquedescribed
iseasilyadaptedtoeithermouseorrhesusIgGsamplesandthusprovidestheabil-
itytostudyhumoralimmuneresponsesinbothanimalmodelsandtheclinic.
The existing study was performed on bulk IgG, which includes various sub-
classes depending on the species, IgG1-4 in human and rhesus, IgG1, 2a/b and
3 in mouse. Given the high sensitivity of the technique, future studies could be
performed on purified IgG subclasses to characterize the diﬀerences in subclass
glycosylation across cohorts. Additionally, the sensitivity allows for characteriza-
tionofantigen-specificantibodies,whichwillcontributetoourunderstandingof
thepathogen-specifichumoralresponse.
In order to support the evolving studies of antibody glycan variation, and its
importance in tuning antibody functionality, we describe a high-throughput ap-
64proachfortheanalysisofthisimmunologicalmarkerthatiswellsuitedtostudiesin
largecohortsandanimalmodels. Ultimately,duetothesimplicityofthismethod,
andwidedistributionofDNAanalyzers,weanticipatethatthistechniquewillex-
pand the analysis of IgG glycosylation across a wide variety of cohorts including
thosecollectedforstudiesofaging,infectiousdisease,vaccination,autoimmunity,
andmore.
65Based on a manuscript in preparation. Technical assistance provided by Kendall
Dionne,JacquelynneTedesco,andAnastassiaMikhailova.
3
GlycosylationofIgGismodifiedinHIV
infection
Changes in the structure of the IgG Fc-attached N-linked glycan can po-
tently modify antibody inflammatory profile as well as its functionality, includ-
ing antibody-dependent cellular cytotoxicity (ADCC) and complement deposi-
tion. Thus, IgG glycosylation is an important regulator of the humoral immune
response. While antibody glycosylation is altered in several immune diseases, in-cludingrheumatoidarthritis,somecancers,andHIVinfection,theparticularsig-
nalsthatdriveglycosylationchangesarenotwellunderstood. GiventhatHIVin-
fectioninducessignificantchangesinbulkFcglycosylation,wesoughttoidentify
the factors associated with these changes. To do this, we measured plasma cy-
tokine concentrations in a cohort of HIV-positive individuals and observed that
specific inflammatory cytokines are associated with the production of inflamma-
tory glycan structures, suggesting a role for general inflammation in driving IgG
glycosylation. Additionally, we sought to determine whether the bulk glycosyla-
tion changes that we observed in HIV-infected individuals are relevant to func-
tion by performing antibody functional assays and we observed a correlation be-
tween specific Fc-glycosylation patterns and strong eﬀector functionality, includ-
ing ADCC, antibody-dependent phagocytosis, natural killer cell activation, and
complement deposition. Finally, we characterized the glycosylation profiles of
antigen-specific anti-HIV and flu antibodies and observed diﬀerences suggesting
that glycosylation regulation occurs at the antigen-specific level. Altogether, this
studyisthefirsttolinkspecificimmunefactorstotheabnormalglycosylationob-
served in HIV infection. Additionally, we have identified an important relation-
shipbetweenpolyclonalIgGglycosylationandspecificantibodyfunctionswithin
an HIV-positive cohort and discovered that glycosylation is likely diﬀerentially
regulated within antigen-specific cells. Ultimately, understanding which immune
signalsdriveIgGglycosylation,andsubsequentantibodyfunction,willbeimpor-
tantfordesigningbothvaccineandtreatmentstrategiesforinfectiousandautoim-
munediseases.
673.1 Background
Antibody function and inflammatory profile is controlled primarily by the con-
stant region or crystallizable fraction (Fc) of IgG, which can act to recruit innate
immunecells[126],inflammatorysignalingmolecules[180],complementdepo-
sition [218], as well as alter the antibody serum half-life [102, 197]. While iso-
type and subclass play an important role in determining much of the antibody’s
functionality [92, 160], it is glycosylation of the Fc that most specifically and po-
tently tunes many of functions of the Ig molecule, including antibody-dependent
cytotoxicityandcomplementdeposition[126,197]. TheIgGFccontainsasingle
N-linkedglycosylationsiteandvariationofthestructureoftheattachedglycanin-
ducessignificantchangesinantibodyfunction[176]. Amerefoursugarsubunits,
fucose,galactose,N-Acetylglucosamine(GlcNAc),andN-Acetylneuraminicacid,
atypeofsialicacid,createarepertoireofover30possibleglycanstructures[230],
eachwithaslightlydiﬀerentinflammatoryandeﬀectorfunctionprofiles[20]. Thus,
glycosylationisanexquisitelysensitiveandpowerfulmodifierofthehumoralim-
muneresponse.
Modificationoftheinflammatoryprofileofanantibodyisprimarilycontrolled
by the addition of galactose and sialic acid [32]. Each Fc-bound glycan has two
possible sites for galactosylation, and the existence of one (G1), two (G2), or no
(G0)galactoseunitscontributestoitsinflammatoryprofile[70]. Antibodieswith-
outgalactosemakeupabout30%ofahealthyindividual’sIgGs[174],butthepro-
portion of agalactosylated antibodies increases dramatically in inflammatory dis-
68easessuchasrheumatoidarthritis[127,165]andHIVinfection[3].
Fullygalactosylatedantibodies(G2)makeupabout20%ofhealthyIgGs[174]
and can have one or two terminal sialic acids, which induce an active anti-inflam-
matory response [209]. Experiments in mice suggest that terminal sialic acids
interact directly with DC-SIGN to mediate anti-inflammatory cytokine cascades
[16], which likely drives the therapeutic eﬀect of intravenous immunoglobulin
treatment in inflammatory autoimmune diseases [14, 17, 27, 100, 198]. In addi-
tion to their role determining an antibody’s inflammatory profile, the presence of
galactose and sialic acid can impact its eﬀector function. Specifically, agalactosy-
lated glycans activate complement deposition by recognition of the exposed Glc-
NAc sugars by the mannose-binding lectin [127], while the presence of terminal
sialicacidsdecreasesADCCactivity[193].
Modificationoftheremainingsugarsubunits,fucoseandthebisectingGlcNAc
(b-GlcNAc), primarily influence antibody eﬀector functions through interaction
withFcreceptors(FcR)[177]. Thesemodificationshavebeenstudiedextensively
in the therapeutic antibody field, where techniques to modify and tune the anti-
body eﬀector functions in vitro have focused on genetic engineering of the gly-
cosylation machinery in order to make potent ADCC or complement recruiting
IgGs [73, 92, 213, 232]). The best characterized IgG sugar addition is that of the
corefucose. Around90% of the Fc glycansin a healthyindividual arefucosylated
[172, 174], but the presence of fucose dampens an antibody’s ADCC activity by
as much as 50-fold [168, 203]. This eﬀect is mediated by an increased aﬃnity of
FcγRIIIAforafucosylatedFcs[63,201]duetosterichindranceofthefucoseinthe
69FcRbindingdomain[141]. Thepotenteﬀectoffucosylationonantibodyeﬀector
functionalityhasledtothewideuseoffucosyltransferase(FUT8)knockoutcells
fortheproductionofmonoclonalantibodiesagainsttumors,inordertooptimize
the ADCC activity of therapeutic antibodies [129]. The addition of a b-GlcNAc
increasesADCCactivityofanattachedantibodyinafucoseindependentmanner
[122,225],alsomediatedbyalterationofFcaﬃnityforFcγRIIIA[55]. Thepres-
ence of this sugar occurs in a small proportion of antibodies in healthy adults, as
lowas10-20%[172,174].
Studies of IgG glycosylation have focused primarily on methods to engineer
optimallyeﬀectivemonoclonaltherapeuticIgGsthroughgeneticmodificationof
cell culture lines [62, 180]. However, in vivo studies have observed that changes
inpolyclonalglycosylationisassociatedwithavarietyofinflammatoryconditions,
includingmultipleautoimmunediseases[23,105,219],cancer[19,41,101],obe-
sity[110,155],aging[110,164]andinfection[3,7,188]. Interestingly,theresolu-
tionofinflammatorysymptomsofrheumatoidarthritisduringpregnancyortreat-
ment is associated with a return to normal IgG galactosylation [217, 227], while
inHIVinfection,treatmentornaturalcontrolofvirusareassociatedwithmainte-
nanceofhighproportionsofG0glycans[3]. Thisapparentmodulationofgalacto-
sylation during inflammation strongly suggests that immune signals can tune the
inflammatoryprofileofantibodies. Whilestudieshavelinkedhighplasmaconcen-
trations of the inflammatory cytokine IL6 with increased proportions of G0 gly-
cans during rheumatoid arthritis [223], the signals responsible for the regulation
of IgG glycosylation during infection have not been explored. Altogether, these
70studiessuggestthatspecificimmunesignalsarecapableofmakingspecificchanges
totheoverallIgGglycan;howevertheparticularimmunesignalsimportantforal-
teringglycosylationremaintobeidentified,especiallyininfectiousdisease.
OurstudysoughttodeterminehowHIVinfectionaﬀectsbulkFc-glycosylation
and determine which types of signals are associated with aberrant glycosylation
during HIV infection. Previous work in our lab has shown that HIV infection
creates significant changes in IgG glycosylation [3, 145], so we have expanded
our study to determine which immune factors are associated with changes in gly-
cosylation in HIV-positive individuals. To do this, we investigated the relation-
ship between glycosylation and age, sex, viral load, CD4 count and concentra-
tionofspecificcytokines. Additionally,wesoughttodeterminewhetherbulkFc-
glycosylation is a relevant factor in determining antibody function by measuring
thefunctionalcapacityofHIV-positiveIgGsandcomparingthiswiththeirglyco-
sylation profiles. Finally, we characterized the glycosylation profiles of IgGs spe-
cific for HIV or influenza and linked gp120-specific antibody glycosylation to its
function in vitro. Ultimately, by understanding the natural mechanisms of glyco-
sylation regulation, we will be able to use specific signals to tune glycosylation to
elicitbetterhumoralimmuneresponsesthroughvaccinationandtreatmentforau-
toimmuneorinfectiousdiseases.
713.2 Methods
Samples
HIV-positiveindividualswererecruitedthroughtheRagonInstituteatMassachu-
setts General Hospital. All donors provided written informed consent and the
Partners Healthcare Institutional Review Board approved this study. Our HIV-
positive cohort included chronically infected individuals naïve to treatment and
acutelyinfectedindividualswithinsixmonthsoftheirpresumeddateofinfection.
Additionally, plasma was collected from a longitudinal cohort of acute patients
overapproximately1.5yearspostinfection. AlargercohortofHIV-infectedindi-
viduals included natural controllers, who maintain low viral loads (<1000) for at
least one year without treatment, as well as chronic progressors on antiretroviral
treatment.
Healthy human subjects with no known active viral infection were recruited
throughBrighamandWomen’sHospitalPhenoGeneticProject. TheInstitutional
Review Board of Partners Healthcare approved the study, and each subject gave
writteninformedconsent.
Fcglycanisolation
Plasma was collected from whole blood and stored at -80◦C until use. IgG was
isolatedusingMelonGelIgGpurificationresin(ThermoFisher)accordingtothe
manufacturer’s instructions. Fc and Fab fragments were separated through enzy-
matic digestion with 40 Units of IdeS (Genovis) and Fc purified using protein
72G magnetic beads (Millipore). N-glycans were released from Fc fragments with
on-bead enzymatic digestion with 100 Units of PNGaseF (NEB). Released gly-
cans were purified by precipitating deglycosylated protein with ice-cold ethanol
and supernatants were dried in a centrifugal evaporator. Dried glycans were fluo-
rescently labeled with a 1:1 ratio of 25 mM 8-aminopyrene-1,3,6-trisulfonic acid,
APTS(LifeTechnologies)in1.2Mcitricacidand1Msodium-cyanoborohydride
in tetrahydrofuran (Sigma Aldrich) at 55◦C for 3 hours. Unreacted dye was re-
movedusingfreshlymade250 μlP2-resin(Bio-Rad)sizeexclusioncolumns.
CapillaryelectrophoresisofFcglycan
Cleaned, labeled glycans were diluted 1:10 in ultrapure water and loaded onto a
3130XLABIDNAsequencer(LifeTechnologies). Glycanswererunthrough36
cmcapillariesofPOP7acrylamidematrixusingtheparametersdescribedin[116].
Peakswerecomparedtothoseofknownglycanstandards(Prozyme)andpeakarea
was calculated for each structure using a custom designed MATLAB script. The
relativeproportionof21individualstructureswascalculatedforeachsampleand
for simple, straightforward presentation of data, glycan structures were summed
intocategoriesbasedongalactosecontent(G0,G1,G2),sialylation,fucosylation
andthepresenceofbisecting-GlcNAc.
Purificationofantigen-specificIgGs
RecombinantHIVproteinsgp120(YU2)andp24(HXBc2)(ImmuneTech)were
biotinylatedonprimaryamineswithalongchainbiotinreagent(ThermoFisher).
73InfluenzaHAproteinswereselectedtocontainapoolofendemicseasonalandvac-
cine influenza strains, including H1N1 (A/Brisbane/59/2007, A/New Caledo-
nia/20/99 and A/Solomon Islands/3/2006), H3N2 (A/Brisbane/10/2007 and
A/Wisconsin/67/X-161-2005)andsubtypeB(B/Florida/4/2006,B/Malaysia/-
2506/2004) all from ImmuneTech. Biotinylated proteins were immobilized in
micro-volume streptavidin resin columns (Agilent). IgG was concentrated to 1-
5 mg/ml and passed over the columns by centrifugation, washed with PBS and
elutedin0.1Mcitratebuﬀer,pH2.9.
Plasmacytokinemeasurements
The concentration of specific cytokines in plasma samples isolated from chroni-
cally HIV-infected individuals were measured using a multiplexed bead-based as-
say(Millipore)accordingtomanufacturer’sinstructions.
Complementdeposition
To measure the capacity of IgGs to recruit the complement component C3b to
the surface of target cells, primary CD4+ cells from healthy HIV-negative donors
werecoatedwithrecombinantgp120andincubatedwithIgGsisolatedfromHIV-
positivedonors,basedontheassaydescribedin[216]. Pooledhumanserumcon-
taining active complement factors was added to the antibody-coated cells and in-
cubatedfor20minutes. Complementdepositionwasmeasuredbystainingcomp-
lement-coated cells using a rabbit anti-human C3b antibody conjugated to FITC
(MP Biomedical) for flow cytometry. A complement response score was calcu-
74latedasthepercentofC3bpositivecellsabovethatofanIgGnegativecontrol.
Antibody-dependentcellularphagocytosis
To determine the capacity of an individual’s IgGs to induce antibody-dependent
phagocytosis,wecoatedstreptavidin-coatedfluorescentbeads(LifeTechnologies)
withbiotinylatedrecombinantgp120andincubatedgp120-coatedbeadswithIgG
fromHIV-positivedonors. Antibody-coatedbeadswereaddedtowellscontaining
THP-1cells(phagocyticmonocytes,AmericanTypeCultureCollection). Cellu-
laruptakeofbeadswasmeasuredusingflowcytometry,andphagocyticscorewas
calculatedbymultiplyingthepercentageofFITCpositivecellsbytheirmeanflu-
orescenceintensity(MFI)ofFITC.AnIgGnegativeconditionwasusedtodeter-
mine antibody-independent phagocytic activity, which was subtracted from the
experimentalphagocyticscore,asdescribedin[5].
Antibody-dependentcellularviralinhibition
Viral inhibition through antibody-dependent eﬀects was measured, as described
in [66], byinfectingprimary CD4+ cells from HIV-negative patientswith the lab
adapted HIV strain JRCSF. Infected cells were incubated with IgGs derived from
HIV-positiveindividualsandnaturalkiller(NK)cellsfromtheautologousCD4+
celldonorwereadded. Viralinhibitionwasmeasuredbydeterminingtheamount
of infectious virus in the cell supernatant at four and seven days after infection.
To measure infectious virus, cell supernatants were added to TZM-bl cells, a ge-
netically modified cell line that produces luciferase when infected with HIV, and
75luciferase production was measured. The viral inhibition assay measures a vari-
ety of potential factors at once, including direct killing of infected cells by acti-
vatedNKs,chemokinemediatedviralinhibition,andcytokine-inducedapoptosis,
amongothers,howevereachoftheseeﬀectscannotbemeasuredinisolationwith
thisassay.
NKDegranulation
We measured the capacity of IgGs to activate NK cells by coating 96-well plates
with recombinant gp120 and adding IgGs from HIV-positive donors. NK cells
from healthy HIV-negative donors were added to antibody-coated wells for six
hours,andNKactivationwasmeasuredbyflowcytometry,usingintracellularstain-
ingforMIP1βandIFNγ,aswellasinternalizationofCD107a,asdescribedin[47].
Rapidfluorometricantibody-dependentcellularcytotoxicity
The ability of IgGs to initiate direct antibody-dependent killing by NK cells was
measured by creating NK targets from CEM cells, a CD4 expressing cell line, by
coatingthemwithrecombinantgp120. Thesecellsweredual-labeledwithanintra-
cellular dye, CFSE, and a membrane dye, PKH, before incubation with IgG from
HIV-positive donors. Labeled cells were incubated with NK cells from healthy
HIV-negative donors for four hours and analyzed by flow cytometry. NK-killed
cells have permeable membranes, so they lose cytoplasmic dye while retaining
their membrane, thus target cell killing was calculated by measuring the percent-
age of CFSE negative, PKH positive cells as a total of double positive cells, based
76on[74].
Statistics
GraphPadPrism6wasusedtographicallyplotdataandperformstatisticalanalyses
asdescribedineachfigure.
3.3 Results
3.3.1 BulkIgGFcglycosylationismodifiedinHIVinfection
In order to characterize IgG glycosylation changes during HIV infection, we ana-
lyzedthebulkFcglycosylationofIgGsfromHIV-positiveandnegativeindividuals
andobservedthatHIVinducessignificantdiﬀerencesinFcglycosylation,includ-
ing an overall increase in agalactosylated structures (Figure 3.1), as has been de-
scribed[3]. Interestingly,weobservedthatHIV-positiveindividualshaveasignif-
icantlygreaterproportionofsialylatedantibodies,whichareknowntohavepotent
anti-inflammatoryeﬀects[16]. Additionally,HIVinfectionisassociatedwithbulk
Fc-glycansthatarelessfucosylatedandmorebisected,whichsuggeststhatIgGsin
HIV-positiveindividualsareassociatedwithgoodeﬀectorfunctionality,giventhe
independent roles of low fucose and high bisection in increasing ADCC activity
[55,201].
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Ǐǐ3.3.2 Bulk Fc glycosylation changes over the course of HIV infec-
tion
TodeterminewhenduringHIVinfectionglycosylationisaltered,weseparatedour
cohortsintoacuteandchronicinfection,accordingtoclinicaldefinitions. HIVin-
fectionisconsideredacutebeforeviralsetpoint,usually3-6monthsafterinfection
[52,64]whilechronicinfectionismarkedbymaintenanceofaviralloadsetpoint.
After separating our cohort by acute and chronic phase, we observed that Fc
glycosylationissignificantlydiﬀerentbetweentheearlyandlatestageofinfection
(Figure 3.2A). In particular, the inflammatory profile of the bulk Fc glycans is in-
creased as patients move from acute to chronic infection, as indicated by higher
proportions of G0 and lower proportions of G2. Interestingly, the sialylation of
Fcs from HIV-positive individuals is most aberrant, as compared to glycosylation
ofIgGsfromuninfecteddonors(graylinesinFigure3.2A),duringtheacutephase
ofinfection. Weobservedthattheproportionofsialylatedstructuresdeclinesdur-
ing the transition to chronicity, thus further increasing the inflammatory profile
of the chronically infected individuals’ Fc glycans. Additionally, the proportion
of bisecting-GlcNAc, which is highest in acute patients, decreases significantly as
the infection progresses to the chronic phase, though never to the level of unin-
fected individuals. Overall, the observation that HIV infection is associated with
distinct glycosylation patterns during the acute and chronic phases suggests that
activechangesinglycosylationoccurduringthecourseofinfection.
ToconfirmthechangesthatweobservedinbulkFcglycosylationbetweenacute
79andchronicallyinfectedHIV-positiveindividuals,weusedsamplesfromaseparate
longitudinal cohort of individuals collected during the acute phase of HIV infec-
tion and tracked for approximately one and a half years after approximate time of
infection. Using at least five time points for each patient, we analyzed the Fc gly-
cosylationovertime. Sinceeachpatienthasadiﬀerentbaselineglycosylationpro-
file,wecalculatedpercentchangesincefirsttimepointforeachcategoryofglycan
to better characterize change over time. Interestingly, we observed a significant
correlationbetweentimepost-infectionandtheproportionofagalactosylated,di-
galactosylated,andsialylatedFcglycans(Figure3.2B).Thesecorrelationssupport
theobservationofatransitionfromhighlysialylatedandgalactosylatedstructures
during acute infection toward less sialylated and more agalactosylated glycans in
the chronic phase, as observed in our cross-sectional acute and chronic cohorts.
Since acute infection is associated with high viral load before the lower viral set
pointofchronicinfection,thesedatasuggestthatthemovetomoreinflammatory
glycanprofilesisnotadirecteﬀectofhighviremia,butthatitisalong-termeﬀect
ofimmunedysregulationcontemporaneouswiththetransitiontochronicHIVin-
fection. In both of our analyses, we observed no change in fucosylation between
acuteandchronicinfection,andyettheproportionoffucosylationissignificantly
lower in HIV infection compared to uninfected individuals. This result is sugges-
tive of an early change in the regulation of fucose addition during HIV infection,
giventhatitisalreadyabnormallylowduringtheacutephaseofinfection. Finally,
while we observed a significant diﬀerence in b-GlcNAc in our initial analysis of
acute versus chronic HIV infection, there was no significant change in b-GlcNAc
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Figure3.2: AcuteandchronicHIVinfectionareassociatedwithdiﬀerentbulkFc
glycosylation patterns. A: Bulk Fc glycans from HIV-positive individuals were ana-
lyzedanddatawereseparateddependingonthephaseofinfection: acute(hatchedbars,
n=39) or chronic (solid bars, n=20). Gray lines indicate median values for uninfected
individuals. Statistical significance was determined using the t-test. B: Bulk Fc glyco-
sylation was measured in a longitudinal cohort of HIV-infected individuals. Changes
were normalized to percent of change since the first time point, which is approximate
to suspected date of infection and time of enrollment. Spearman correlation r- and p-
valuesareexpressedforeachcategoryofglycanstructure. Statisticallysignificantvalues
are in black, others in gray (n = 10 individuals with 5 time points each). Gray dotted
lineindicates100%offirsttimepoint.
81proportion in our longitudinal cohort. This may be due to changes that occur at
alatertimepointininfectionthanthe1.5yearsofourlongitudinalcohort,orthe
change may have a much lower slope than we have statistical power to detect in
ourcohort.
3.3.3 Glycosylation changes are associated with inflammatory cy-
tokinesinHIVinfection
Given that HIV infection is associated with significantly altered Fc glycosylation,
wesoughttoinvestigatetheassociationbetweenmarkersofinfectionandglycosy-
lationchanges. Todothis,weassembledacohortoftwohundredHIV-infectedin-
dividuals,includingthechronicuntreatedpatientsdescribed,togetherwithchronic
patients on treatment as well as individuals who control virus at low levels with-
outtreatment. First,wedeterminedwhetherpreviouslydescribedfactors,suchas
ageandsex,wereaconfounderinouranalysisofFcglycosylation. Ageisknownto
correlatewithchangesinglycosylation,inparticulargalactoseisknowntoincrease
withage[54,110,164]. However,inourcohort,wedidnotobserveanysignificant
changeinglycosylationinrelationtodonorage(Figure3.3). Thisisnotsurprising,
giventhattheagerangeinourcohortonlyspanstwoandahalfdecadesfrom20to
45, which is the range of ages in which the fewest changes in glycosylation occur
[164]. PreviousstudieshavealsodescribeddiﬀerencesinIgGglycosylationbased
onsex[42],soweseparatedourcohortbysexanddeterminedthattherewereno
significantdiﬀerencesbetweenmalesandfemalesinbulkFcglycosylation. These
data indicate that observed diﬀerences in Fc glycosylation in our cohort are not
82Female
Male
0
20
40
60
%
 
o
f
 
I
g
G
 
F
c
 
G
l
y
c
a
n
Agalactosylation
Female
Male
0
20
40
60
Sialylation
Female
Male
50
60
70
80
90
100
Fucosylation
Female
Male
0
10
20
30
Bisection
A 
B 
C  D 
0 500 1000 1500
0
20
40
60
80
100
CD4 Count
CD4 Count
100 1000 10000 100000
0
20
40
60
80
100
Viral Load
%
 
o
f
 
I
g
G
 
F
c
 
G
l
y
c
a
n
Viral Load
20 30 40
0
20
40
60
80
100
Age (years)
%
 
o
f
 
I
g
G
 
F
c
 
G
l
y
c
a
n
Age
Agalactosylated
Fucosylated
Bisected
Sialylated
'JHVSF ȗȗ #VML 'D HMZDPTZMBUJPO JT OPU BTTPDJBUFE XJUI BHF TFY WJSBM MPBE PS
$%Ș #VML 1SPQPSUJPO PG UPUBM BHBMBDUPTZMBUFE 	ZFMMPX
 TJBMZMBUFE 	QVSQMF
 GVDPTZ
MBUFE 	SFE
 BOE CJTFDUFE 	CMVF
 'D HMZDBOT JO B DPIPSU PG ȖȔȔ )*7QPTJUJWF JOEJWJEVBMT
XBTQMPĪFEBHBJOTU"BHFJOZFBST#TFY$WJSBMMPBEBOE%$%ȘDPVOU /PTJHOJG
JDBOUDPSSFMBUJPOTXFSFPCTFSWFEVTJOH4QFBSNBODPSSFMBUJPOUFTU
ǐǋbeingdrivenbytheseconfoundingfactors.
Next, we investigated the relationship between clinical markers of HIV infec-
tion and glycosylation in our cohort. First, we hypothesized that viremia drives
theinflammatoryIgGglycosylationofchronicallyinfectedHIV-positiveindividu-
als. However,weobservedthattherewasnosignificantrelationshipbetweenviral
loadandglycosylationprofiles,evenifweexcludecontrollersandtreatedindivid-
uals, both of whom have low viral loads, but high inflammatory glycan signatures
[3]. Another important marker of immune dysregulation in HIV is CD4 count,
however,wesimilarlysawnosignificantassociationsbetweenCD4countandgly-
cosylationprofile. Theseresultssuggestthatthefactor(s)thatdriveglycosylation
diﬀerencesinHIVinfectionarenotdirectlyassociatedwithviremiaordiseasepro-
gression,asmeasuredbyCD4count.
Givenourresultsshowingthatcommonmeasuresofdiseaseprogressiondonot
correlate with changes in IgG glycosylation, we sought to determine whether in-
flammatory cytokine signatures are associated with abnormal IgG glycosylation.
Inordertoidentify specific markers of inflammation in our HIV cohort, wemea-
sured the plasma concentration of a variety of cytokines, including some specifi-
callyassociatedwithsystemicinflammationinHIVinfectionthatremainelevated
even during treatment or natural control [43, 121]. We observed that IgG glyco-
sylationprofilesarecorrelatedwiththeplasmaconcentrationofcertaincytokines
(Figure3.4). InparticularIP10ismoststronglyassociatedwithinflammatorygly-
can structures, including low levels of digalactosylated and sialylated glycans as
well as an increased proportion agalactosylated and bisected glycans. Given that
84Figure3.4: Glycanchangesareassociatedwithinflammatorycytokines. Plasma
concentrations were measured using a multiplexed bead-based assay and the relation-
ship between specific cytokines and glycan structures was determined using Spearman
correlations. Spearmanr-valuesarerepresentedontheheatmap,withpositiveassocia-
tionsinyellowandnegativeinblue. Correlationp-valuesforsignificantassociationsare
shownineachbox(*=p<0.05,**=p<0.01,****=p<0.0001).
85IP10, or CXCL10, is produced in response to IFNγ production [125], this sug-
gestsalinkbetweengeneralsystemicinflammatorysignalsandspecificglycosyla-
tionchanges,inparticulartowardinflammatoryglycanprofiles. Wealsoobserved
thatC-reactiveprotein(CRP)ispositivelyassociatedwithagalactosylatedglycans,
ashasbeendescribedinrheumatoidarthritis[223]. Thisrelationshipisunsurpris-
inggiventhatCRPlevelsriseduringtheacutephaseofautoimmuneandinfectious
phasesofinflammation,andplasmaCRPlevelsarewidelyusedasaclinicalmarker
of inflammation [48]. We observed a positive correlation between RANTES, a
lymphocyteattractingchemokineproducedprimarilybyTcells[207],andfuco-
sylation, which is the first observation of an association between cytokine con-
centration and the level of fucosylation in vivo, suggesting a role for T cell signal-
ing in guiding B cell glycosylation of IgG. Finally, we observed a negative corre-
lation between agalactosylation and both IL4, a potent activator of B and T cells
[243]andthecloselyrelatedcytokine,IL13[57,246],bothofwhichareproduced
during Th2 type responses and are essential for B cell antibody class switching
[34,240]. Thesecytokinesaregenerallyconsideredanti-inflammatory[56,139],
despitetheirBcellactivatingeﬀects,suggestingthattheymaybeabletodecrease
IgG inflammatory profiles by inducing anti-inflammatory IgG glycosylation. In-
terestingly, we did not observe an association between IL6 and increased agalac-
tosylated IgG glycans, as has been described in rheumatoid arthritis [223]. This
lack of association may be due to the diﬀerence in inflammatory profiles elicited
duringautoimmuneversusinfectiousdisease.
863.3.4 BulkIgGglycosylationisassociatedwithspecificantibodyef-
fectorfunctions
Ultimately,therelevanceofglycosylationinvivodependsonthelinkbetweengly-
cosylation and antibody function. While the functional eﬀect of specific glycans
iswell-characterizedinmonoclonalantibodies[62],theeﬀectofsialylationinin-
travenousimmunoglobulintherapyistheonlywellcharacterizedglycosylationef-
fect in polyclonal IgGs [244]. Thus, we sought to determine whether the glyco-
sylation of a polyclonal population of antibodies is relevant to antibody eﬀector
function, including the ability to induce complement deposition, phagocytosis,
antibody-dependentviralinhibition, NK cell activation or ADCC.To do this, we
measured the functional activity of antibodies from a cohort of 200 HIV-positive
individualsandcomparedtheIgGfunctionalactivitiestotheirglycosylationpro-
files. Spearman correlations were calculated and r-values were plotted in a heat
maptovisualizerelevantrelationships(Figure3.5). Weobservedassociationsbe-
tweenspecificIgGglycanstructuresandeﬀectorfunctionspreviouslyidentifiedin
studiesofmonoclonaltherapeutics. Inparticular,ahighproportionofagalactosy-
latedstructures(G0)isassociatedwithbettercomplementdepositionandADCC
activity [178, 242] and decreased fucosylation or sialylation are correlated with
stronger ADCC in the RF-ADCC assay [161, 193]. Interestingly, we also identi-
fied previously undescribed relationships, such as a positive correlation between
highlyagalactosylatedstructureswithphagocyticactivityaswellasapositiveasso-
ciationbetweenb-GlcNAccontentandbothcomplementdepositionandgeneral
NK activation. The association of b-GlcNAc with these functions highlights two
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ǐǐpreviouslyunknowneﬀectsofthismodificationonantibodyfunction.
Overall,thesignificantassociationsbetweenglycanmodificationsandantibody
functionality suggest that the eﬀect of glycosylation is not limited to monoclonal
therapeutics, but may also be relevant in polyclonal populations. While the re-
sultsoftheseassaysaredrivenbytheactivityofantigen-specific,inparticularanti-
gp120, antibodies, we have observed that the functionality of the tiny fraction of
antigen-specific IgGs can be partially predicted by the glycosylation patterns of
the bulk Fc. Of note, we did not observe strong correlations between any glycan
structuresandADCVI,butbecausethisassaymeasuresacomplicatedinteraction
of a variety of cellular and viral factors, so may be that glycosylation alone cannot
predictviralinhibitioninthisassayveryaccurately.
3.3.5 Antigen-specific antibodies have distinct glycosylation pro-
files
Giventhatthefunctionalassaysweperformedaredrivenbyantigen-specificanti-
bodies,particularlyagainstgp120,wesoughttocharacterizetheglycosylationpro-
filesoftheseHIV-specificantibodies. Incomparisonoftheanti-HIVresponse,we
alsoanalyzedtheglycosylationofantibodiesdirectedagainstinfluenzavirusinthe
samecohortofHIV-positivedonors. Todothis,weisolatedgp120-,p24-,andin-
fluenzaHA-specificantibodiesandanalyzedtheattachedglycansbycapillaryelec-
trophoresis. Since the volume of isolated antigen-specific antibodies is small, we
analyzedtheglycanoftheintactIgG,whichincludesFabdomain-attachedglycans
inadditiontothefunctionallyrelevantFcglycosylation,sowecomparedantigen-
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Figure3.6: Glycosylationisregulatedonanantigenspecificlevel. Antigen-specific
antibodies against gp120 (n = 103), p24 (n = 47), and influenza HA (n = 40) were
isolatedfromacohortofHIV-positiveindividualsandtheattachedglycansofthesean-
tibodies were compared to bulk IgG glycosylation (n =193). Mean galactosylation is
expressed as stacked bars, mean proportions of sialylation, fucosylation, and bisection
(with GlcNAc) are represented as mean with standard deviation. Statistical signifi-
cance between means was determined using Kruskal-Wallis test with Dunn’s multiple
comparisontest(*=p<0.05,***=p<0.001,****=p<0.0001).
90specificglycanstothoseofintactbulkIgGsfromthesameHIV-positivedonors.
In comparing the glycosylation profile for each antigen-specific antibody, we
observedthateachgroupofspecificantibodieshasasignificantlydiﬀerentglycosy-
lationprofile(Figure3.6). Specifically,HIV-specificantibodiesagainstgp120and
p24havesignificantlymoreinflamedstructureswithhigherproportionsofagalac-
tosylated and lower proportions of sialylated glycans. The HIV-specific antibody
glycans also have higher fucosylation compared to bulk antibodies, suggestive of
lowerADCCactivity. Interestingly,bisectionishigheringp120-specificantibod-
ies, even in comparison to p24 antibodies, which, based on the role of b-GlcNAc
in ADCC [55], is suggestive of increased eﬀector function. The antigen-specific,
butnon-HIV,anti-HAantibodieshaveaprofilemorelikethatofbulkIgGglycans
ineverycategory,exceptinb-GlcNAc,forwhichtheHA-specificantibodieshave
alowerproportion,suggestiveoflessADCCactivity.
Interestingly, the intact HIV-specific antibodies have an Fc-like glycosylation
profile, with less sialylation and more fucose, while the bulk and flu-specific anti-
bodieshaveprofilesthatsuggestthepresenceofFabglycosylation[84,136]. This
eﬀect may be due to a decreased tolerance for Fab glycosylation in antibodies di-
rectedagainstHIVantigenoradiﬀerenceintheregulationofglycosylationinHIV-
specific B cells. Ultimately, these data strongly suggest that glycosylation is regu-
latedattheleveloftheantigen-producingBcell,notonlyinresponsetosystemic
inflammatorysignals.
Given our analysis of the glycosylation of gp120 specific antibodies, we can
moreaccuratelylinktheglycanprofilewiththemeasuredgp120-specificantibody
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ǑǊfunction. We compared the same functional activity data used in Figure 3.5, to
the glycosylation profiles of gp120-specific IgGs and observed many of the same
relationships (Figure 3.7), including associations between complement and G0,
ADCCandlowfucose,andNKactivationandbisection. Whilethereislesspower
intheantigen-specificanalysis(n=103versus200),weobservedmostofthesame
associations. Given these similarities, it is unsurprising that the bulk Fc glycan
profile can predict the functionality of the relatively small proportion of gp120-
specificantibodies.
3.4 Discussion
Thisstudyisthefirsttocharacterizeassociationsbetweenparticularcytokinesand
changes in the proportion of specific bulk Fc glycans in HIV-infected individu-
alsandtoshowthatbulkFc-glycosylationisarelevantmeasureofoveralleﬀector
functionalityinHIVinfection.
ByinvestigatingtheeﬀectofHIVinfectiononbulkglycosylation,weobserved
thattheFcglycansofIgGsfromHIV-positiveindividualsaresignificantlyaltered,
during both acute and chronic infection, as summarized in Figure 3.8. While un-
infected patients have mostly G1 glycans, acute HIV infection is associated with
asignificantriseinG2andsialylatedglycans,whichswingsdramaticallytoahigh
proportionofG0,asialylatedstructuresupontransitiontochronicinfection. This
findingsuggeststhatduringtheacutephase,patientscanovercometheinflamma-
tory signals induced by the virus through the generation of compensatory anti-
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Ǒǌinflammatory structures. Ultimately, however, the immune system may be over-
whelmed by HIV-induced immune dysregulation, resulting in an increase in pro-
ductionofinflamedG0structuresasthegenerationofanti-inflammatorysialylated
structures decreases. Another change in glycosylation during the transition from
acute to chronic HIV infection occurs in the proportion of b-GlcNAc, which is
highestduringacuteinfection,butdecreasesduringchronicinfection,thoughnot
tothelevelobservedinuninfectedindividuals. Thekineticsofthischangesuggest
that the signals that drive production of bisected Fc glycans are present early in
infection,butwaneasindividualsprogresstochronicinfection.
Given that HIV infection induces changes in bulk glycosylation, we sought to
identifysomeofthesignalsassociatedwiththesechanges. WeobservedthatIP10
and CRP are both associated with higher proportions of inflammatory glycans,
suggestingthatsystemicinflammationisamajordeterminantoftheIgGglycosyla-
tionprofile. AlinkbetweeninflammatorycytokinesandagalactosylatedIgGshas
beenobservedinautoimmunedisease,includinganassociationwithbothIL6and
IL2concentration[29],however,theserelationshipswerenotobservedinourco-
hort, suggesting that regulation of glycosylation during autoimmune disease and
infectious disease may be diﬀerent. Further characterization of the factors driv-
ing glycosylation change in diﬀerent infections will further elucidate the types of
signalsimportantforthisprocess.
Furthermore, it is apparent that the glycosylation of gp120- and p24- specific
antibodiesaremoresimilartoeachotherthanthatofantibodiesagainstinfluenza.
This finding shows that despite the inflammatory signals associated with changes
95inthebulkFcglycosylationprofile,withinanindividual,glycosylationisregulated
at the level of the antigen-producing cell. Importantly, this suggests that glycosy-
lation is being regulated within individual B cells and that signals specific to the
antigen or the environment at the time of exposure to antigen can influence the
ultimateglycosylationpatternontheproducedIgG.
Importantly,weobservedthatthemodificationofglycosylationinapolyclonal
population is relevant for determining the functionality of antibodies from HIV-
positive donors. We found links between glycan structures and Fc-mediated an-
tibody functions including complement deposition, NK activation, phagocytosis
and ADCC. This shows for the first time that glycosylation of polyclonal IgGs is
relevantfordeterminingeﬀectorfunctioninvitro.
In investigating the eﬀect of HIV infection on bulk Fc glycosylation, this study
identified a set of cytokine signals that are associated with glycan changes in HIV
infectionandweobservedalinkbetweentheFcglycosylationofHIV-specificIgGs
andtheirfunctionalactivity. Mostinterestingly,weobservedthatglycosylationis
also regulated at the level of the antigen-specific B cell. These results point to the
importanceofdoingfurtherworktodeterminewhichspecificsignalsandstimuli
drivetheregulationofIgGglycosylation,whichwillultimatelybeapotenttoolfor
programmingantibodyeﬀectorfunctionandinflammatoryprofilethroughvacci-
nation.
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Antigen-specificIgGglycosylationis
directedbyHIVVaccination
In human studies of HIV and non-human primate models of SIV and SHIV
infection,non-neutralizingantibodiesareeﬀectiveatpreventingorcontrollingvi-
ralinfection. Thus,determininghownon-neutralizingantibodiesareinducedwill
provide insights into the design of a potentially protective vaccine strategy. Non-
neutralizing antibody functions, including antibody-dependent cellular cytotoxi-city,complement-dependentcytotoxicityandantibody-dependentphagocytosis,
are modulated by the immune response in two major ways: through changes in
antibody subclass and alterations of the N-linked glycan of the Fc domain. How-
ever, little is known about how glycosylation is tuned and programmed in vivo.
To better understand IgG glycosylation in HIV vaccine recipients, we used capil-
laryelectrophoresistocharacterizebulkandvaccine-specificglycosylationinHIV
vaccinerecipients. Usingsamplescollectedfromavaccinetrialusinganadenovi-
ral vector (IPCAVD-004) administered in three geographical areas, we observed
significantdiﬀerenceinbulkIgG-glycanpatterns,associatedwithgeographicallo-
cation. However, vaccine-specific antibodies have glycosylation patterns distinct
from that of bulk Fc, suggesting that vaccine specific signals can overcome sys-
temic diﬀerences in bulk antibody glycosylation. In contrast, comparison of two
diﬀerentvaccines,(IPCAVD-004andVAX003,arecombinantprotein/alumvac-
cine)inducedsignificantlydiﬀerentglycosylationpatternsonvaccine-specifican-
tibodies, suggesting that diﬀerent signals during vaccination can tune the elicited
IgG-glycan. These results show for the first time that vaccines elicit specific and
distinctglycosylationpatternsonantigen-specificIgGsthataredistinctfrombulk
glycosylation patterns. Given the importance of IgG-glycosylation in mediating
eﬀector functions, which are important in non-neutralizing protection from HIV
infection,thisstudyhighlightstheimportanceofincludingantigen-specificglycan
profilinginfutureimmunemonitoringandcorrelatesanalysesofvaccinetrials.
984.1 Background
To date, the only known correlate of decreased risk of infection in an HIV vac-
cinetrialisstrongnon-IgAtitersagainsttheV1andV2loopsofIgGelicitedinthe
Thai RV144 trial [80, 182]. Secondary correlates analysis revealed an additional
association between protection and strong antibody-dependent cellular cytotox-
icity (ADCC) activity [30, 80, 182]. However, the RV144 trial only temporarily
elicited these antibodies, with protection waning one year after the final vaccine
boost [103, 109, 186]. Thus, it remains unknown how eﬀective and sustained ef-
fectorantibodiescanbeelicitedagainstHIVthroughvaccination. Understanding
all the correlates of protection for an eﬀective and sustained vaccine-elicited re-
sponse is an important goal for moving the field forward. However, it is still un-
known what factors may be important for or correlated with a long-lasting, pro-
tectiveresponseagainstHIV.Thus,characterizingarangeofbiophysicalandfunc-
tional parameters of the vaccine-elicited immune response, including factors that
havenotyetbeenassociatedwithprotection,isofvitalimportance. Theseparam-
eters should include factors associated with non-neutralizing functional activity,
suchasantibodysubclass,titer,breadthofbinding,andN-glycosylation.
Whilemostnon-HIVvaccineselicitprotective,neutralizingantibodies,anHIV
vaccine has yet to successfully elicit strong neutralizing responses. Thus, the in-
duction of non-neutralizing antibodies with potent eﬀector functionality repre-
sentsapotentiallypowerfulapproachforcreatingasuccessfulvaccine[212,237].
It is well established that antibodies with potent eﬀector functionality, especially
99ADCC,andpossiblyantibody-dependentcellularphagocytosis(ADCP)andcom-
plement-dependentcytotoxicity(CDC),caninhibitviralreplicationinvitro[224],
isassociatedwithslowerprogressionofAIDS-relateddisease[66,115],andispro-
tectiveinanimalstudiesofpassiveantibodytransferandvaccination[21,75,143].
Thus,thesetypesofantibodyresponses,iflong-lived,couldbethekeytoaneﬀec-
tivevaccinestrategy.
Eﬀector functionality in antibodies is regulated strongly by IgG subclass selec-
tion, which is known to aﬀect IgG aﬃnity for Fc receptors [92, 156, 160]. Inter-
estingly, the RV144 vaccine elicited higher proportions of the IgG3 subclass than
VAX003 [45], resulting in more polyfunctional antibodies in RV144. However,
IgG3 antibodies usually wane quickly after an initial spike in production, which
mayexplainthelackofsustainedprotectioninRV144. Beyondsubclass,antibody
glycosylation is a rapid and potent regulator of inflammatory profile and eﬀector
function. The IgG glycan, positioned in the CH2 domain of the constant region
(Fc),isanasparagine-linkedbiantennarystructurewhichvariesbasedonthepres-
ence or absence of four sugar subunits: galactose, sialic acid, fucose and an N-
Acetyl-glucosamine(GlcNAc)thatbisectsthearmsofthestructure. Galactosyla-
tionallowsfortheattachmentofterminalsialicacids,bothofwhicharepotentreg-
ulators of the inflammatory profile of the IgG. Agalactosylated IgG structures are
associated with active inflammatory disease, including rheumatoid arthritis [166,
227] and chronic HIV infection [3], while sialic is actively anti-inflammatory, in
particular during therapeutic administration of pooled healthy immunoglobulin
to treat autoimmune disease [15, 27, 49, 244]. In addition to the modulation of
100antibody inflammatory profiles, changes to the fucose and bisecting-GlcNAc (b-
GlcNAc) content can potently aﬀect eﬀector function. A lack of fucose increases
ADCCactivityofmonoclonalantibodiesby50-100fold[201,203],whilethead-
ditionofb-GlcNAccanincreaseADCCactivity[55]. Lackofsialicacidmayplay
aroleinincreasingADCCactivity[193]whileconflictingdataexistontheeﬀect
ofgalactoseonADCC[32,113]. Recruitmentofcomplementisaidedbyagalac-
tosylatedantibodies[127]andadditionalrelationshipsbetweeneﬀectorfunction
and glycosylation likely exist, but remain uncharacterized. Altogether, the pres-
enceorabsenceofthesefoursugarsubunitsallowsforatheoreticalpotentialof36
diﬀerent glycan structures, each with the capacity to diﬀerentially drive eﬀector
functionality and inflammation. This level of specificity makes Fc glycosylation a
potentially potent mechanism for harnessing specific eﬀects of the humoral im-
muneresponse.
Given that glycosylation is a powerful regulator of non-neutralizing antibody
functions and is modified during autoimmune disease and natural infection, this
studysoughttodeterminewhetherglycosylationcanbespecificallyalteredthrough
vaccination. To do this, we characterized both bulk Fc and vaccine-induced an-
tibody glycosylation elicited in a vaccine trial that used the same adjuvant and
immunogen in three geographically distinct populations. Additionally, we inves-
tigated glycosylation in a trial that used an alternative adjuvant and immunogen
combination. We observed that while bulk Fc glycosylation is highly dependent
on geography, the vaccine-elicited antibody glycosylation is not aﬀected by this,
butisdrivenbyparticularsignalswithinthevaccinepreparation.
1014.2 Methods
VaccineCohorts
TheIPCAVD-004vaccinetrial(clinicaltrials.govID:NCT01215149)wasasafety
andimmunogenicitytrialofacombinationofadenovirusvectorsexpressinggp120
ENVA. Both Ad26 and Ad35 vectors were used in combination or alone in three
testsites: theUnitedStates,EastAfrica,andSouthAfrica. Fourarmsweretestedin
eachlocationwiththreeorsixmonthsbetweenprimeandboostusingeitherAd26
followed by Ad35, vice versa, or two doses of the same vector. The trial recruited
low-risk,HIV-negativeadultstoreceive5x10¹⁰viralparticlesperdoseintramuscu-
larly. Individualsintheplacebogroupreceivedadoseof10mMTris/HClbuﬀer.
During the course of our study, we were blinded and do not know which experi-
mental group each sample belongs to, only which geographical region they were
collected in. Samples used in this study were collected at peak immunogenicity,
twoweeksafterfinalimmunization.
The VAX003 trial was a phase 3 eﬃcacy trial administered in Thailand, but in
a high-risk population of intravenous drug users (IVDUs) (clinicaltrials.gov ID
NCT00006327). ThistrialusedsevendosesofthesameAIDSVAXB/E,arecom-
binantgp120cladeB/Ewithalumastheadjuvant. Allsamplesusedinthisstudy
werecollectedatpeakimmunogenicity,twoweeksafterthefinalvaccination.
102Fcglycanpreparation
Plasma was collected by vaccine trial staﬀ and stored at -80◦C until use. IgG was
isolatedusingMelonGelIgGpurificationresin(ThermoFisher)accordingtothe
manufacturer’s instructions. Fc and Fab fragments were separated through enzy-
matic digestion with IdeS (Genovis) and Fc purified using protein G magnetic
beads (Millipore). N-glycan was released from Fc fragments with on-bead treat-
mentwithPNGaseF(NEB).Releasedglycanswerepurifiedbyprecipitatingdeg-
lycosylated protein with ice-cold ethanol and dried in a centrifugal evaporator.
Driedglycanswerefluorescentlylabeledwitha1:1ratioof25mM8-aminopyrene-
1,3,6-trisulfonic acid, APTS (Life Technologies), in 1.2 M citric acid and 1 M
sodium-cyanoborohydride in THF (Sigma Aldrich) at 55◦C for 3 hours. Unre-
acted dye was removed using freshly made 250 μl P2-resin (Bio-Rad) size exclu-
sioncolumns.
Antigenspecificantibodypurification
Vaccine-specific gp120 antigens (EnvA for IPCAVD and a 1:1 mix of A244 and
MNforRV144andVAX003,ImmuneTech)werebiotinylatedonprimaryamines
usingalongchainbiotinreagent(Thermo)andfreebiotinwasremovedusingdial-
ysis. Biotinylated antigen was immobilized on micro-volume streptavidin resin
columns(Agilent)andpurifiedIgG,concentratedto3-5mg/mlwasrunoverthe
columns using centrifugation. After washes with PBS, antigen-bound antibodies
were eluted with 0.1 M citrate buﬀer, pH 2.9 and IgGs were immediately treated
withPNGaseFtoreleaseattachedN-glycansforanalysis.
103Capillaryelectrophoresis
Cleaned, labeled glycans were diluted 1:10 in ultrapure water and loaded onto
a 3130XL ABI DNA sequencer (Life Technologies). Glycans were run through
36cmcapillariesofPOP7acrylamidematrixusingparametersdescribed[116]. Gly-
canpeakswerecomparedtothoseofknownglycanstandards(Prozyme)andpeak
area was calculated for each structure using a custom designed MATLAB script.
The relative proportion of 21 individual structures was calculated for each sam-
ple, and for simple, straightforward presentation of data, glycan structures were
summed into categories based on galactose content (G0, G1, G2), sialylation, fu-
cosylationandthepresenceofbisecting-GlcNAc.
Statistics
Univariate data were analyzed in GraphPad Prism Version 6.0e for Mac (Graph-
PadSoftware, SanDiego, California)forstatisticalsignificanceandgraphicalrep-
resentation. Statistical tests used are indicated for each figure. Multivariate anal-
yses were performed using MATLAB and Statistics Toolbox Release 2013b (the
MathWorksInc.,Natick,Massachusetts).
Multivariateanalysis
Using the proportions of all the individual glycan structures, of which 21 were
identifiedbyourcapillaryelectrophoresistechnique,wecanusemultivariateanal-
ysis to analyze the power of the observed variables to separate the samples col-
lected at each test site in an unbiased manner. Using principal component analy-
104sis (PCA), a descriptive function is generated for each experimentally measured
variableusingweightedvaluesofalltheotherinputvariables. Thesefunctionsare
rankedbytheirabilitytodescribethevariabilityofthewholedatasetandwecan
visualize the separation of the data sets by plotting the results of the best func-
tion(x-axis)againstthesecondbestfunction(y-axis). Thisscoresplotrepresents
theoutputofthetwobestdescriptivefunctionsforeachsampleanalyzed. PCAis
unbiased and attempts to group the data based solely on the variation within the
complete data set, so after the analysis is complete, we can color the sample dots
according to which group they belong to and assess the separation of each group
ofsamples. Finally,toassesswhichvariablesaremostimportantinseparatingour
dataset,wecanplottheweightsofeachvariableintherespectiveanalysisinaload-
ingsplot. Theloadingsplotcontainsallthevariablesmeasuredandthelongertheir
vector,themorepowertheycontributedtothedescriptivefunction.
4.3 Results
4.3.1 Bulk IgG Fc-glycosylation is highly variable in different re-
gions
To determine whether geography impacts bulk IgG glycosylation, we analyzed
samplesfromanHIVvaccinetrialinwhichthesameadjuvantandimmunogenwas
administered in three distinct geographical regions. IPCAVD-004 used a combi-
nationofAd26andAd35vectorsexpressingEnvA,andwasadministeredtohealthy
adultsintheUnitedStates,Kenya/Rwanda(EastAfrica),andSouthAfrica. Com-
105paringthevaccinerecipientsinthesethreetrials,weobservedthattherearesignif-
icantdiﬀerencesinthebulkIgGFc-galactosylationandsialylationintheenrolled
individuals,whichisindependentofthevaccine-specificresponsesincetheyallre-
ceivedthesamevaccine(Figure4.1A).Inparticular,individualsfrombothAfrican
regions have significantly higher proportions of agalactosylated (G0) Fcs. While
both African groups have lower sialylation than US vaccinees, East Africans have
thelowestbulkantibodysialylation. Giventheroleoflowgalactoseandsialylation
in determining the inflammatory activity of antibodies [126], these data suggest
thatatbaseline,bulkantibodyglycosylationinAfricaisassociatedwithinflamma-
toryglycosylation,withEastAfricanshavingthemostinflammatoryprofile.
Inadditiontochangesingalactoseandsialicacid,fucoseandbisecting-GlcNAc
alter antibody function [55, 201]. Interestingly, in our South African cohort, we
observed higher fucosylation of bulk Fc compared to either group (Figure 4.1A).
Additionally,SouthAfricanshavelowerbisecting-GlcNAccomparedtobothgroups.
A high fucose, low b-GlcNAc glycan is predicted to have low functional activity.
These results highlight that even within a single continent, significant diﬀerences
mayariseinantibodyglycosylationofbulkantibodies.
TogainamorecompleteunderstandingofthediﬀerencesinbulkIgGglycosy-
lation, we next used principle component analysis to compare the antibody gly-
can profiles among our groups, including all 21 glycan structures that we detect
by capillary electrophoresis. In multivariate space, the three arms of the vaccine
trial are very well resolved (Figure 4.1B), suggesting that fundamentally diﬀerent
glycosylation profiles exist within each region. This separation is largely driven
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ǉǈǏinflammatoryglycanstructures,asshownbythelengthofthevectorsontheload-
ingsplot,whichillustratesthepowerofeachvariabletocontributetoresolvingthe
separation among the cohorts. Interestingly, the East African vaccinees separate
completelyfromtheothergroups,whiletheSouthAfricanandUSrecipientsover-
lapslightlyintheirbulkFcglycanprofiles,suggestingthatwhilevariationsinbulk
Fc glycosylation exist among all groups, there are greater diﬀerences between the
twoAfricancohorts.
4.3.2 Vaccinationelicitsglycosylationpatternsindependentofbulk
glycosylation
Given the significant diﬀerences in Fc glycosylation patterns based on geographi-
callocation,wesoughttodeterminewhethervaccine-elicitedantibodyglycosyla-
tionissimilarordistinctfromthebulkFcglycosylationprofile. Toinvestigatethis,
vaccine-elicited antibodies were purified from bulk IgG using vaccine-matched
gp120 antigens in a subset of vaccinees from each region. These antibodies were
thenanalyzedusingcapillaryelectrophoresistocharacterizetheattachedglycans.
Strikingly, the vaccine-elicited antibodies are significantly diﬀerent from the bulk
glycans(Figure4.2A).InmultivariatePCA,thereisnooverlapoftheantibodygly-
cosylation profiles of antigen-specific (maroon) and bulk antibodies (blue) (Fig-
ure4.2A,right). Asillustratedintheloadingsplot(Figure4.2A,right),thissepara-
tionisdrivenprimarilybydiﬀerencesinfucosylationandsialylation. Thisanalysis
showsthatvaccine-specificantibodyglycosylationisfundamentallydiﬀerentthan
bulk antibody glycosylation, suggesting that vaccine signals actively tune distinct
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ǉǈǑchangesinantigen-specificglycosylation.
4.3.3 Vaccine-induced antibody glycosylation is independent of re-
gionalbulkglycosylationdifferences
Because the vaccine induced glycan profile is distinct from bulk IgG glycosyla-
tion,wenextaimedtodeterminewhetherregionaldiﬀerencesinbulkFcglycosy-
lation influence the vaccine-elicited glycan profiles by comparing the glycan pro-
file of gp120-specific antibodies across the three geographical regions. Interest-
ingly, antigen-specific antibody glycosylation in vaccinated individuals does not
diﬀeramongthegeographicallocationstested(Figure4.2B).Whilethereisatrend
toward a smaller proportion of bisecting-GlcNAc in the Kenyan/Rwandan pop-
ulation, this is the opposite of the profile observed in the bulk Fc glycosylation
(Figure4.1A),demonstratingadisconnectbetweenvaccine-specificandbulkan-
tibody glycosylation. These data strongly suggest that vaccine-induced glycosyla-
tion changes are not directly influenced by the bulk Fc-glycosylation diﬀerences
weobservedamonggeographicalregions.
4.3.4 Vaccineselicitdistinctglycosylationprofiles
Given that IPCAVD-004 is an adenovirus-vectored vaccine and this vaccine reg-
imen elicited similar glycosylation in all recipients, regardless of geographical re-
gion, we sought to determine whether diﬀerent vaccine preparations induce dis-
tinctglycosylationpatterns. Toinvestigatethis,wecomparedtheantigen-specific
glycosylation of antibodies elicited by the IPCAVD vaccine compared to the gly-
110can profiles of gp120-specific antibodies in recipients of VAX003 an alum adju-
vanted recombinant gp120 vaccine administered in Thailand. Interestingly, we
observedthattheIPCAVDvaccine-inducedmoreanti-inflammatoryglycanstruc-
tures,withhigherproportionsofG2andsialicacidcomparedtoVAX003(Figure
4.3). IPCAVD also induced an increased proportion of bisected structures, sug-
gesting that these antibodies may possess increased functionality, based on the
roleofbisecting-GlcNAcinincreasingADCCactivity[55]. Takentogether,these
data demonstrate that distinct vaccines can specifically tune the glycosylation of
antigen-specific antibodies, independent of bulk Fc glycosylation. Given the im-
portanceofglycosylationinmodulatingantibodyeﬀectorfunctions,andourdata
demonstrating the capacity for vaccines to induce specific glycosylation profiles,
this study points to the need to include antigen-specific glycosylation profiling as
acriticalqualitativemeasureofnon-neutralizingvaccine-inducedhumoralimmu-
nity.
4.4 Discussion
This study is the first to analyze antibody glycosylation in the context of vaccina-
tion against HIV with the goal of understanding vaccine-elicited antibody glyco-
sylation. In this study, we show that while geography has a significant impact on
bulk Fc glycosylation patterns, a particular vaccine can overcome systemic diﬀer-
encestoelicitsimilarglycanpatternsonvaccine-inducedantibodiesindependent
of bulk Fc glycosylation. In contrast, we observed that distinct vaccines elicit dif-
ferentantigen-specificantibodyglycosylationprofiles.
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ǉǉǊThe observed population level diﬀerences in bulk Fc glycosylation are possi-
bly due to factors such as endemic infections, especially given the eﬀect of some
natural infections on bulk glycosylation [3, 7]. The impact of nutrition may also
be important in determining bulk Fc glycosylation based on established associa-
tions between body mass index and production of inflammatory IgG glycosyla-
tion[110,155]. TheroleofgeneticsindeterminingFcglycosylationinthisstudy
cannotbeexcluded,thoughotherstudiesofgeneticallydistinctpopulationshave
notobservedsuchstrongdiﬀerencesamonggroups[172]. Additionally,thefind-
ing that vaccines elicit the same glycosylation patterns in people with diﬀerent
bulk glycosylation patterns suggests that genetic diﬀerences are not a major fac-
tor. While we did not analyze the glycan profile of the diﬀerent IgG subclasses,
anotherimportantfactorinproducingdiﬀerentglycosylationpatternsmaybethe
baseline proportions of particular IgG subclasses within each group as each IgG
mayhavediﬀerentglycosylationpatterns[106,239].
Despite the diﬀerences in Fc glycosylation driven by geographical region, we
observednodiﬀerenceintheglycanpatternsofantigen-specificIgGselicitedbya
given vaccine preparation. The ability of an adenovirus vectored vaccine to elicit
thesameglycosylationpatterninantigen-specificantibodies,independentofbase-
line bulk Fc glycosylation, is an encouraging finding that suggests that vaccine-
specific signaling can tune the antibody glycan irrespective of existing humoral
responses. This will be very important for HIV vaccination since vaccine recipi-
entsarelikelytobehighlyheterogeneousintheirpre-exposuretofactorsthatalter
theirexistingIgGglycosylationprofiles.
113Importantly,whiletheadenoviralvectorelicitedaspecificglycosylationprofile
onantigen-specificantibodies,IgGselicitedbyalumadjuvantedrecombinantpro-
tein vaccine VAX003, were significantly diﬀerent. The diﬀerences illustrate that
vaccine-specific signals, either through adjuvant, immunogen, or a combination
of the two, can actively program the glycosylation of IgG. Interestingly, given the
eﬀectofb-GlcNAconeﬀectorfunction[55],IPCAVDmayhaveproducedhighly
eﬀective antibodies with a high proportion of bisecting-GlcNAc containing gly-
cans. Additionally, in comparison to VAX003, the IPCAVD vaccine-induced less
inflammatoryglycanstructures,withhigherproportionsofsialylatedglycansand
fewer agalactosylated glycans, which may be similarly advantageous in producing
an eﬀective vaccine response without inducing an overly inflammatory response.
However, since the IPCAVD-004 study was a safety and immunogenicity trial,
not an eﬃcacy trial, protection data is unavailable, so the relationship between
vaccine-specific antibody glycosylation and protection cannot be established at
thistime.
ThisstudyisthefirsttoshowthatbulkFcglycosylationdoesnotdirectlydeter-
minevaccine-inducedantibodyglycosylation,rathervaccine-specificsignalsdrive
the generation of antigen-specific glycan profiles. Ultimately, these data suggest
that a combination of specific adjuvants and/or immunogens can elicit a specific
glycanpatternwithaprotectivebalanceofinflammatoryandfunctionalcharacter-
istics.  
1144.5 Additionaldata
RV144 was a phase 2B vaccine trial administered in Thailand to low-risk, HIV-
negative adults (clinicaltrials.gov ID NCT00223080). The trial consisted of six
immunizations with a canary pox viral vector, ALVAC HIV (vCP1521), which
containsHIVenv,gag,andpolgenes,andtwoimmunizationsofalum-adjuvanted
recombinant gp120 (AIDSVAX B/E), administered concurrent with the last two
ALVAC doses. The trial lasted 24 months and all samples used in this study were
collectedatpeakimmunogenicityattwoweeksafterfinalvaccination.
4.5.1 HIVriskfactorisapotentialdriverofIgGFc-glycosylation
Two major vaccine trials in Thailand recruited volunteers from groups with dif-
ferent risk factors. RV144 was administered in 18-30 year-old, TB-negative men
and women with low risk of HIV acquisition and VAX003 recruited intravenous
drug users (IVDUs) 20-60 years-old. Given that geographical factors can influ-
ence bulk Fc glycosylation, we hypothesized that IV drug use may also influence
IgG glycosylation. In these trials, we benefited from having a number of samples
fromplaceborecipients,sowecouldcomparebulkglycosylationwithandwithout
vaccineadministration.
First,todeterminewhethereithervaccinepreparationalteredbulkFc-glycosyla-
tion, vaccine (solid bars Figure 4.4A) and placebo (hatched bars) recipient IgG
glycanswerecompared,andwefoundthatnosignificantdiﬀerencesexistbetween
thegroupsineithertrial,showingthatneithervaccinepreparationwasabletosig-
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ǉǉǎnificantlyalterbulkFcglycosylation.
Whencomparingthetwovaccinerecipientgroups,however,weobservedthat
IVDUs enrolled in the VAX003 (maroon, Figure 4.4A) trial, have significantly
more inflamed glycan structures than the low-risk RV144 trial participants (blue,
Figure4.4A),asindicatedbyhigherproportionsofagalactosylatedandlowerpro-
portions of sialylated Fc glycans. Additionally, VAX003 recipients have a slightly
increased proportion of bisected glycan structures (Figure 4.4A), indicative of a
morefunctionalantibodyglycanprofiles.
Interestingly,whenweanalyzedalltheindividualglycanstructuresusingmulti-
variateanalysisbyPCA,thepopulationsdonotseparateaswellasinthegeograph-
icallydistinctpopulations(Figure4.4B).Thissuggeststhatriskfactor,inparticular
IV drug use, is not as influential on Fc glycosylation as other, as yet unidentified,
environmentalfactors. Whiletheglycanstructuresassociatedwithinflammation,
galactose and sialic acid, were again on the periphery of the loadings plots, these
variablesdidnotresolvethetwopopulationsverywell.
Finally, given that RV144 and VAX003 recipients have such diﬀerent bulk Fc
glycosylation profiles, we sought to determine whether the vaccine-elicited anti-
body glycosylation was also diﬀerent. The comparison of these two trials is es-
pecially important since RV144 proved to be a mildly protective vaccine, while
VAX003 was not. In comparing RV144 to VAX003, however, it is important to
notethatwhilethesetrialsbothusedAIDSVAXB/E,analumadjuvantedrecom-
binant gp120, the RV144 trial also contained six doses of ALVAC, a canary pox
vector expressing HIV proteins. Despite these relatively diﬀerent preparations,
117RV144andVAX003trialsareoftencomparedbecausetheyaresimilarbothintheir
use of AIDSVAX B/E and in geographical location. Since RV144 was protective,
we expected to observe some diﬀerences between the glycosylation of vaccine-
elicited antibodies in each trial, however we observed no diﬀerences in any cate-
goryofglycanstructure(Figure4.5).
AdditionalDiscussion
In further investigation of IgG glycosylation after HIV vaccination, we compared
two similar, but distinct trials. We saw that VAX003 placebo recipients and vac-
cinees have significantly more inflamed glycan structures in their bulk Fcs than
RV144 participants. This eﬀect is likely driven by the inflammatory eﬀect of in-
jected drugs, which are associated with general inflammation and infections that
are not commonly observed in healthy populations [36, 199, 221], though this
relationship has not been directly established. Additionally, we observed an in-
creased proportion of bisecting-GlcNAc in the VAX003 cohort, suggesting that
theeﬀectsofgeneralinflammationorinfectionmayinfluenceb-GlcNAcaddition
along with galactose and sialic acids, however little is know about natural regula-
tionofIgGglycanbisection.
While VAX003 and RV144 were diﬀerent vaccine preparations, they are often
compared to each other to attempt to identify potential correlates of protection
in RV144. Surprisingly, we observed that the use of ALVAC in the RV144 vac-
cine strategy did not elicit diﬀerences in vaccine-specific antibody glycans, when
compared to the AIDSVAX only preparation. The similarity between the glycans
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ǉǉǑof these two trials suggests that the role of the AIDSVAX portion of the vaccine
drovetheselectionofIgGglycosylationpatternsmorethanthecanarypoxvector.
Since the combination of AIDSVAX and ALVAC elicited the same glycan profile
as AIDSVAX alone, it is apparent that glycosylation was not a dominant factor in
the eﬃcacy of RV144. However, this does not discount the possibility that using
a specific combination of adjuvants and immunogens will drive the production
of antigen-specific antibodies with optimal glycosylation patterns for protection
frominfection.
120TechnicalassistanceprovidedbyJustinEusebio,KendallDionne,andJacquelynne
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Glycosyltransferaseexpressionisaltered
byinnateandadaptivesignals
IgG glycosylation is modified during viral infection, autoimmune disease,
and in response to vaccination, which indicates that immune signals can regulate
antibody glycan structure. However, it is still unknown which specific signals are
importantforelicitingparticularstructuresandwhetherglycosylationchangesare
transient or programmed within antibody-producing cells. Identifying relevantglycosylation regulatory signals is an important step in understanding how par-
ticular IgG glycan structures can be elicited through vaccination, so, to begin to
understand this, we investigated the eﬀect of three types of stimuli on the tran-
scriptionalprofileofglycosylationmachineryinhumanBcells: a)innate,includ-
ing toll-like receptor (TLR) signaling, and adaptive including b) B cell receptor
(BCR) stimulation and c) T cell help. Ultimately, these results are important for
understanding how changes to the IgG glycan are influenced by specific immune
signals,whichwillallowfortheelicitationofspecificandpotentantibodyeﬀector
functionsforlong-lasting,protectivehumoralimmuneresponses.
5.1 Background
Modulation of antibody eﬀector function is important for eﬀective monoclonal
antibody therapeutics against specific types of cancer [130, 213] and protection
from natural infections, including HIV [61]. In the case of therapeutic antibod-
ies, extensive eﬀorts to characterize and tailor the eﬀector function of antibodies
produced in vitro have focused on modulating functionality through alteration of
theglycanstructureoftheIgGFc[94]. Forinstance,theinteractionofIgG1with
FcγRIIIA is 50 fold better when the IgG glycan does not contain a core fucose
[201]. Additionalalterationsoftheglycanstructureofinvitro-producedantibod-
ies include changes to increase the proportion of bisecting (GlcNac) structures,
which can further increase binding to the ADCC activating receptor, FcγRIIIA
[55]. IgG sialylation is inversely correlated with induction of inflammatory sig-
nals [16, 27], while low galactose content is associated with inflammation in au-
122toimmuneandinfectiousdisease[145,165]. WhiletheeﬀectofIgGglycosylation
iswell-characterized,thespecificmechanismsofregulationoftheseglycosylation
changesinvivoitisstillpoorlyunderstood.
AlterationofIgGglycosylationoccursduringthecourseofimmunologicaland
inflammatorydiseases,inparticularincancer[41,101,111],autoimmunedisease
[219,226],andspecificinfections,[145,188]. Theseexampleshighlightthatgly-
cosylationisanaturallyregulatedpartoftheimmuneresponseandthatitislikely
controlledbyimmunologicalsignals. Ourdata,presentedinChapter3,showthat
inflammatory cytokines are associated with changes in IgG glycosylation during
HIVinfection,whilesignalsdeliveredduringvaccinationcanspecificallytunethe
antigen-specificantibodyglycosylation,asshowninChapter4.
Attachment of asparagine-linked N-glycans to IgGs occurs in the ER and early
Golgicompartments,wherehighlyspecificglycosylationenzymessequentiallyadd
sugar subunits to the glycan as the protein transits through the Golgi apparatus
[231]. Regulationoftheseenzymes,eithertranscriptionallyorpost-translationaly,
isrelevanttochangesinglycanstructure[149],howeverthemechanismsandsig-
nalsresponsibleforitsregulationarenotwellunderstood,especiallyinthecontext
ofimmuneactivation. Thus,wesoughttounderstandhowglycosylationmachin-
eryinBcellsisregulatedbyidentifyingspecificstimulithatalterthetranscription
ofglycosyltransferases(GTs).
Patternrecognitionreceptors,inparticulartoll-likereceptors(TLRs),areaclass
ofinnateimmunereceptorsthatcandetectcommonlyproducedviralorbacterial
molecules[112]. Theirprimaryfunctionistocreatearapid,non-specificresponse
123while the adaptive response is initiated to create a highly specific response [222].
Their role in adaptive immune cells, however, may be a more complex one allow-
ingcellsoftheinnateoradaptiveresponsetogaininformationaboutthepathogen
in question, including whether it is bacterial or viral, intra- or extracellular [167].
Thus, we hypothesized that the activation of TLRs, many of which are expressed
inBcellsofhumans[53],mayplayaroleintuningtheantibodyresponsebypro-
grammingIgGglycosylationchanges,andsubsequentlyalteringtheeﬀectorfunc-
tionofantibodies.
This study was designed to identify specific immune signals, in particular ago-
nists of TLRs, that alter the glycosylation profiles of IgGs using a transcriptional
profiling approach. Ultimately, given the importance of IgG glycosylation in de-
termining antibody function, understanding which signals regulate and program
IgGglycosylationwillbecrucialfordevelopingvaccinestrategiesthatelicitpotent,
long-lasting,protectiveantibodyresponses.
5.2 Methods
IsolationofBcells.
LeukaphoeresisofHIVnegativedonorswereobtainedfromtheMGHbloodbank.
B cells were purified to >99% CD19+ by using B cell Rosette Sep reagent (Stem
Cell, Canada) followed by a magnetic bead-based B cell Negative-Selection Easy
Sep (Stem Cell, Canada), according to the manufacturer’s directions. Cells were
culturedinRPMIsupplementedwith10%fetalbovineserumat1-2x10⁶cells/ml.
124Stimulationofexvivocells.
Tolllikereceptor(TLR)agonistsweredilutedinendotoxinfreewaterandadded
to B cell cultures at indicated final concentrations: TLR 1/2-Pam3CSK4 (200
ng/ml), TLR 3- Poly(I:C) (10 μg/ml), TLR 4- Ultra pure LPS (1 μg/ml), TLR
5- Ultrapure Flagellin (100 ng/ml), TLR 2/6- Pam2CSK4 (100 ng/ml), TLR 7-
Imiquimod(5 μg/ml),TLR7/8-CL097(5 μg/ml),andTLR9-CpGODN2006
(5 μg/ml) all from Invivogen (San Diego, CA). Anti-BCR stimulations were per-
formed using donkey anti-human IgG F(ab)2 (Jackson Immuno Research) at 10
μg/ml. Soluble Mega-CD40L (Enzo Life Sciences) was used at 100 ng/ml. After
16hoursofstimulation,mediawasremovedandcellswerelysedinRLTbuﬀer.
TranscriptionalProfilingofGlycosylationEnzymes
RNA was extracted using an RNeasy kit (Qiagen), cDNA was synthesized using
MuLV reverse transcriptase (NEB) and used in TaqMan FAM hydrolysis probe-
based qPCR (Life Technologies). Specific glycosyltranferase genes measured in-
cludedB4GALT1,ST6GAL1,FUT8andMGAT3;GAPDHwasusedasahouse-
keepinggene.
Statisticalanalysis
Datawereplotted,andstatisticswerecalculatedusingGraphPadPrism. Statistical
testsusedareindicatedforeachfigure.
1255.3 Results
5.3.1 Glycosyltransferases associated with inflammatory IgG gly-
cosylationareregulatedinacoordinatedmanner
ToexploretheroleofTLRsinIgGglycosylation,westimulatedBcellswithTLR
agoniststo determine whether thesesignals couldalter the transcription of genes
responsible for IgG glycosylation. We found that B cells stimulated with agonists
ofTLR4,7/8or9significantlydecreaseexpressionofthegenesthatregulategalac-
tosylation and sialylation B4GALT1 and ST6GAL1, respectively (Figure 5.1A).
Giventheroleofgalactoseandsialicacidindeterminingtheinflammatoryprofile
ofIgG[150],thesensitivityofthesegenestoTLRstimulationsuggeststhatthere
isacoordinatedresponsetoinflammatorysignals. Thecoordinatedexpressionof
B4GALT1 and ST6GAL1 is predicted given their closely related functions in in-
ducing inflammatory profiles. Of note, human B cells are not thought to express
TLR8[59],sotheobservedeﬀectofCL097maybeduetoastrongerinteraction
ofthisagonistwithTLR7thantheTLR7-onlyagonistImiquimod. Additionally,
thoughBcellsdonotexpressTLR4,thepotentnatureofLPSmayhaveactivated
thesmallnumberofnon-Bcellsinourcultures(<2%),whichmayhavestimulated
Bcellsindirectlythroughcytokineproduction.
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Figure 5.1: Transcription of glycosyltransferases associated with inflammation
is altered by TLR stimulation. A: Analysis of B4GALT1 and ST6GAL1, galacto-
syltransferase and sialyltransferase, respectively, expression in B cells stimulated with
TLR agonists for 18 hours. B: Expression of FUT8, fucosyltransferase and MGAT3,
GlcNAc-transferase, in B cells stimulated with TLR agonists for 18 hours. Statisti-
cal analysis was performed using Wilcoxon paired t-test to the unstimulated condition
(n=13)*=p<0.05,**=p<0.01,***=p<0.001.
1275.3.2 Glycosyltransferasesassociatedwitheffectorfunctionality
areresistanttochangeafterinnatestimulation
In contrast to the coordinated expression of the GTs associated with inflamma-
tory glycosylation profiles, we observed distinct expression profiles for the GTs
thataddeﬀectorfunction-modulatingsugars,fucoseorbisecting-GlcNAc(Figure
5.1B). We observed that none of the tested TLR stimulations altered expression
of the fucosyltransferase FUT8. Given the eﬀect of fucose, which can increase
ADCC activity by 50-fold [168], this resistance to expression changes may be a
consequence of the importance and potency of fucosylation. In contrast, though
similarly important for eﬀector function [55], MGAT3 expression is increased in
responsetotheactivationofTLR5byflagellin.
5.3.3 BCRengagementdown-regulatesexpressionofglycosyltrans-
ferases
Inadditiontoinnatesignals,BcellsareinfluencedbyactivationoftheirBCRand
interaction with other cells, both adaptive and innate. As part of the adaptive im-
munesystem,BcellsreceivesignalsthroughrecognitionofantigenthroughtheB
cell receptor (BCR), which activates the humoral response to produce antibody
[202]. AdditionalactivationsignalscomefromT-cells,whichexpressCD40Land
interactwithBcellCD40toinduceexpansionandantibodyproductionwithinthe
antigen-specificBcells[131]. ToexploretheroleoftheseadaptivesignalsonIgG
glycosylation, we used an anti-IgG reagent, in a F(ab)2 format to prevent ligation
128ofFcγ receptorsontheBcells,andasolubleCD40LreagenttorecapitulateTcell
help.
WeobservedthatactivationofmemoryBcellsusinganti-IgGtocrosslinkBCRs
inducedsignificantdown-regulationofallmeasuredGTexpression(Figure5.2A).
ThisisnotsurprisinggiventhepotencyoftheBCRsignalingpathway. Thisstrong
andnon-specificdecreaseinexpressionmaybearesultofachangeinthemetabolic
pathwayafterastronglyactivatingsignal,perhapsduetoproliferationinresponse
tosimulatedantigen-recognition.
By combining innate stimuli with BCR engagement, we observed that down-
regulation of ST6GAL1 expression is additive since TLR 7 and 7/8 agonists in-
duce a further decrease in ST6GAL1 beyond the α-IgG-alone condition (Figure
5.2B). Additionally, TLR 9 stimulation significantly decreases expression of both
B4GALT1 and ST6GAL1. Interestingly, the eﬀect of BCR ligation with TLR 9
activation induces lower expression of MGAT3 and FUT8. This example of spe-
cific down-regulation of these genes is suggestive of a synergistic eﬀect between
theadaptiveBCRactivationsignalandtheinnateTLR9activationpathways.
5.3.4 T-cellhelpisamodulatorofinnateimmunesignals.
To recapitulate T cell signaling, soluble CD40L was used to stimulate ex vivo B
cells. We observed that CD40L alone does not significantly alter the expression
ofmostoftheGTsexceptB4GALT1,whichisdown-regulated(Figure5.3A).For
themostpart,theexpressionofGTswithsCD40Lstimulationhasthesameprofile
ofthatwithTLRstimulationalone(Figure5.3B).However,theadditionofinnate
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Figure5.2: TranscriptionalanalysisofBcellswithorwithoutBCRcrosslinking.
A:Bcellswerestimulatedwithα-IgGfor18hoursandquantitativeRT-PCRwasusedto
measureGTexpression. Pairedt-testwasperformedtodeterminestatisticallysignificant
diﬀerences (n=12). B: B cells were stimulated with α-IgG in addition to TLR agonists
asdescribedpreviously. StatisticalanalysiswasperformedusingWilcoxonpairedt-test
toα-IgG-alonecondition(n=12)*=p<0.05,**=p<0.01,***=p<0.001.
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Figure 5.3: Soluble CD40L induces synergistic GT expression changes with in-
nate immune signals. A: B cells were stimulated with soluble CD40L for 18 hours
and quantitative RT-PCR was used to measure GT expression. Paired t-test was per-
formed to assess statistically significant diﬀerences (n=8). B: B cells were stimulated
with soluble CD40L in addition to TLR agonists as described previously. Statistical
analysis was performed using Wilcoxon paired t-test to CD40L alone condition (n=8)
*=p<0.05,**=p<0.01,***=p<0.001.
131stimulation,throughTLRs,inducedchangesintheexpressionofMGAT3,which
ismoresensitivetoTLR7orTLR9ligationinthepresenceofsCD40L,suggesting
thatthesepathwaysaresynergisticintheirregulationofthisGT.
5.4 Discussion
Given the alteration of IgG glycosylation during inflammatory autoimmune dis-
ease and infections [3, 165, 188], the antibody glycan is clearly regulated by im-
munological signals. In this study, we sought to identify some of the particular
signalsthatdrivespecificchangesinIgGglycosylationsothatthesesignalscanbe
used to elicit more eﬀective humoral responses through vaccination. This is the
first study to investigate the eﬀect of a variety of innate and adaptive immune sig-
nalsanddeterminewhichsignalscanalterGTexpressioninhumanBcells.
InhumanBcells,weobservedthatgalactosylationandsialylationarethemost
susceptible to changes in expression since B4GALT1 and ST6GAL1 are down-
regulated in response to a variety of signals, including agonists of the intracellu-
lar nucleic acid sensors, TLR 7, 8, and 9, as well as adaptive B cell receptor liga-
tion. The rapid and strong action of decreased galactosylation and sialylation is
supportedbythefactthatchangesingalactosecontentisthemostcommonmod-
ificationtoantibodyglycosylationduringdiseases,includingrheumatoidarthritis
[11],cancer[41],andHIVinfection[117,145]. Thecoordinatedmodificationof
galactoseandsialicacidglycosyltransferaseshighlightshowimportantchangesin
theIgGinflammatoryprofileareforfastandpotentresponsestopathogens.
132In contrast to the observed inflammatory response, the eﬀector function alter-
ingsugars,fucoseandbisecting-GlcNAc,aremoreresistanttochange,whichmay
beaconsequenceoftheimportanceofthesesugarsindeterminingtheactivityof
the humoral response and their significant potential to increase antibody eﬀector
functions, including ADCC and complement. This potent activity likely require
careful regulation to prevent strong auto-reactive responses. We observed that
FUT8 expression is especially resistant to change, except in the presence of BCR
activation,whichstronglyshutsdownexpression. Itisinterestingtonotethatthe
adaptive signal of BCR activation is the only stimuli tested that has a strong ef-
fectonFUT8expression,suggestingaroleforchangesinfucosylationduringthe
initial stages of B cell activation when a cell recognizes its cognate antigen. We
observed that the GlcNAc transferase gene MGAT3 is the only GT gene whose
expressionincreasesinresponsetothestimulationconditionstested,whichisin-
terestinggiventhatitspresenceincreasesfunctionalityinADCC[55],andpossi-
blycomplementandNKcellactivation(Chapter3).
Whiletheresultsofexvivostimulationshighlightthetypesofinnateandadap-
tive stimuli that are important for tuning glycosylation of IgG, it is important to
note that these ex vivo stimulations may not directly link to eﬀects observed in
vivo, so animal studies will be required to clarify the role of adjuvants on deter-
mining antibody glycosylation. Ultimately, the results of this study show that the
expression of genes important for IgG glycosylation can be altered by innate and
adaptive signals, which will be useful for designing new vaccination strategies to
elicitspecificglycanstructuresonantigen-specificIgGs.
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Conclusions
TheabilitytoregulateandtuneIgGglycosylationwillprovetobeapower-
fultoolinelicitingprotectivenon-neutralizingantibodyresponsesthroughvacci-
nation. Thisdissertationsoughttoidentifysomeofthesignalsimportantforreg-
ulating IgG glycosylation and test whether specific immune signals can programIgG glycosylation during immunization. As described, we observed that bulk Fc
glycosylationisalteredduringthecourseHIVinfectionandthatthegenerationof
particular Fc glycan structures is associated with the concentration of specific in-
flammatorycytokines. Weshowedthatininfectionandaftervaccination,antigen-
specific antibodies can have glycan patterns that are independent of the bulk IgG
glycan profile and that diﬀerent vaccines can drive the production of specific gly-
canpatterns. Furthermore,weobservedthatparticularIgGglycosylationprofiles,
bothinbulkandantigen-specificantibodies,areassociatedwithIgGfunctionality
in a polyclonal population. Finally, by stimulating human B cells ex vivo we ob-
served that innate and adaptive immune signals can induce significant changes in
theexpressionofglycosyltransferasesinBcells. Altogether,thispresentsuswitha
hypothetical model of IgG glycosylation regulation, discussed below, which pro-
videsahostofnewresearchquestionstoexplore.
6.1 Dissertationsummary
6.1.1 InflammatorysignalsareassociatedwithchangesinbulkIgG
glycosylationduringnaturalinfection
Using a novel approach to analyzing IgG glycans, as described in Chapter 2, we
profiled bulk Fc glycosylation in HIV infection and found that during acute in-
fection, bulk Fc glycans are mostly sialylated, a modification associated with de-
creasedinflammation. Duringthetransitiontochronicinfection,theIgGglycans
become more inflamed, with an increase in agalactosylated structures. We ob-
135servedthatthisaberrantglycosylationinchronicHIVinfectionisassociatedwith
the concentration of inflammatory cytokines, in particular IP10 and C-reactive
protein(Figure3.4). Thisledustohypothesizethatsystemicinflammatorysignals
can drive B cells to produce more inflamed glycan structures on their antibodies.
Whilethisisanimportantobservation,theultimategoalofvaccinationistoelicita
highlyspecificimmuneresponsethatisindependentofthebulkresponse,inorder
tosafelyandeﬀectivelypreventinfection.
6.1.2 Glycosylationisregulatedatanantigen-specificlevel
Toinvestigateglycosylationontheantigen-specificlevel,weagainusedtheglycan
analysistechniquewedeveloped,butonthetinyfractionofthetotalantibodypop-
ulation that is directed against specific antigens. In the context of HIV infection,
weisolatedantibodiesagainstgp120andp24, aswell asanti-influenzaantibodies
against hemagglutinin (HA), as described in Chapter 3. Additionally, we charac-
terized the glycosylation of the vaccine-elicited anti-gp120 antibodies after HIV
vaccination in Chapter 4. In both cases, we observed that antigen-specific anti-
bodieshaveglycosylationprofilesthatareindependentofthebulkIgGglycosyla-
tion. In HIV infection, we showed that glycans of anti-gp120 and -p24 antibod-
ies are significantly diﬀerent than those of bulk IgGs, and each other, while anti-
HAantibodiesaremoresimilartobulk,thoughstillsignificantlydiﬀerent(Figure
3.6). Aftervaccination,weobservedthatdespitesignificantdiﬀerencesinthebulk
Fc glycan profile of vaccinees from diﬀerent geographical regions, the IgG glycan
elicited by the same vaccine preparation was the same among all groups (Figure
1364.2B). Interestingly, however, diﬀerent vaccine preparations elicited diﬀerent gly-
cosylationprofilesonthevaccine-specificantibodies(Figure4.3). Takentogether,
thesedataprovideevidencethatregulationofIgGglycosylationoccursatthelevel
oftheantigen-specificBcell. Incombinationwithourpreviousfindingssupport-
ingaroleforsystemicsignalsinregulatingIgGglycosylation,theantigen-specific
glycosylation data suggest that more specific signals, such as those provided by
virusorvaccineadjuvants,canoverridesystemicsignalstoproducespecificglycan
patterns. Thesedatahighlightthatparticularglycosylationpatternscanbeelicited
by a specific set of signals, even in populations of vaccinees with heterogeneous
baselineIgGglycosylationprofiles.
6.1.3 Polyclonal antigen-specific glycosylation is associated with
particularantibodyfunctions
Given that the ultimate goal of altering antibody glycosylation through vaccina-
tion is to modulate antibody eﬀector functions, we sought to determine whether
these polyclonal glycosylation changes are relevant for antibody function. To do
this, we profiled both the bulk Fc glycosylation and gp120-specific antibody gly-
cans and compared them to the results of a variety of antibody eﬀector function
assays (Figures 3.5 & 3.7). Interestingly, we observed significant correlations be-
tweenmultiplefunctionsandparticularantibodystructures,includingpreviously
described relationships between low galactose and complement activity and low
fucose and ADCC activity. We also observed relationships that have not been
described previously, in particular between bisecting GlcNAc and both NK cell
137activation and complement-recruiting activity. While these associations are not
conclusiveevidencefortheroleoftheIgGglycanindeterminingparticularinvivo
functions, they strongly suggest that polyclonal IgG glycosylation is relevant for
determiningantibodyfunction.
6.1.4 Innateandadaptivesignalscanalterglycosyltransferaseex-
pressioninBcells
Given that IgG glycosylation appears to be regulated at both the systemic, bulk
level and the more focused, antigen-specific level, we were interested in identify-
ingsomeofthesignalsthatdriveIgGglycosylationchanges. Whiletheassociation
with bulk glycosylation and inflammatory cytokines is interesting in the context
ofautoimmunityandinflammatorydisease,wearemostparticularlyinterestedin
programmingprotectiveresponsesagainstspecific pathogens. Thus, weareinter-
ested in what types of signals act directly on B cells and could be used in a vac-
cine. This led us to investigate the role of toll-like receptor (TLR) agonists in al-
tering the transcription of IgG glycosylation machinery. As described in Chapter
5,wefoundthattheactivationoftheseinnateimmunereceptors,inparticularthe
intracellular nucleic acid sensors, strongly increases the potential to produce in-
flammatory glycans structure, with lowered galactosyltransferase and sialyltrans-
ferases expression. We also observed that innate stimuli require additional adap-
tivesignals,eitherCD40LorBCRcross-linking,toaltertheexpressionofthegly-
cosyltransferases (GTs) that add sugars associated with eﬀector function, fucose
and bisecting-GlcNAc. This suggests that the glycan changes associated with in-
138flammationarehighlysensitivetoinnatestimulation, whiletheeﬀectorfunction-
altering GTs are much more stable in their expression. The observed stability of
fucose and b-GlcNAc altering enzymes highlights the importance and functional
power of these sugars and may be an important mechanism to reduce the risk of
developingnon-specificorself-directedantibodieswithstrongeﬀectorfunctions.
6.2 AhypotheticalmodelofIgGglycosylation
Given the results described in this dissertation, we can begin to develop a hypo-
theticalmodeloftheregulationofIgGglycosylationwithinBcells,showninFig-
ure6.1. WehypothesizethatBcellsthathavenotbeenexposedtoanantigenhave
a baseline, or default, glycosylation program. This program likely produces a gly-
canthathasonegalactose,nob-GlcNAcandacorefucose,basedonthebulkIgG
glycosylation structures that we have observed in healthy adults. Once this B cell
isexposedtoantigen(AinFigure6.1),avarietyofsignalscanacttotunethegly-
canprogramwithintheBcell. ThesesignalsmayincludethoseprovidedbyTcell
help,aswellasdirectBCR-antigeninteractions. Additionalinformationmaycome
fromtheinnateimmunereceptorsthatsensethepathogenaswellasthecytokine
milieuthattheBcellexperiencesasitinteractswithitsantigen. Thecombination
ofthesesignalsmayhelptheBcelldeterminewhetherthepathogenisbacterialor
viral, intra- or extra-cellular, and subsequently drive the production of antibodies
withtheappropriateeﬀectorfunctions. Forinstance,intracellularpathogensmay
requiregoodADCCactivitytokillinfectedcells, while, ontheotherhand, extra-
cellularpathogensareunaﬀectedbyantibodieswithgoodADCCactivity,butare
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ǉǌǈespeciallysusceptibletoantibodiesthatrecruitstrongphagocyticactivityorcom-
plement deposition. Thus, we hypothesize that B cells can sense and respond to
informationaboutapathogenbyproducingthemostappropriateantibodyglyco-
sylationpattern.
Wehaveobservedthatchangestotheeﬀectorfunctionmodifyingsugars,fucose
andb-GlcNAcareespeciallydiﬃculttoelicitthroughsignaling, possiblybecause
theyarealreadyprogrammedwithinthememoryBcellsthatwehavetested. This
led us to hypothesize that these GTs may be epigenetically controlled, which is
supported by evidence of epigenetic programming of some glycosyltransferases
[87,146,191]. Epigeneticprogrammingwouldallowforpermanent,inthecaseof
CpGmethylation,orlong-lived,inthecaseofhistonemodification,programming
ofGTexpression,thussettingaparticularprogramofglycanstructurewithinthe
cell.
GivenevidenceofsystemicchangesinIgGglycosylation,inparticularduringin-
flammatorystatesofdisease,wehypothesizethattheregulationofgalactosylation
and sialylation is more labile than that of fucosylation. Given our data showing
that galactose and sialic acid are often modified in infection and autoimmunity,
and that the galactose and sialic acid-adding GTs are quickly down-regulated in
response to a variety of stimulation conditions, we believe that these changes are
elicited quickly and are potentially transient. Thus, we hypothesize that memory
B cells, when exposed to a new inflammatory state (B in Figure 6.1), as signaled
through innate immune or cytokine receptors, can modify the inflammatory IgG
glycosylation program within the B cell. To produce the types of changes we ob-
141serve ex vivo, we hypothesize that these GT genes are sensitive to a variety of fac-
tors that may include specific transcription factors and microRNAs. The ability
to change the inflammatory profile of IgG using these mechanisms allows for the
rapid,temporarymodificationofIgGgalactosylationandsialylation,whichcanbe
restoredtotheoriginalprogramgivenareturntoanormalinflammatorystate(C
inFigure6.1). Wehypothesizethatremovalofinnateimmuneorcytokinesignals
willremovethetransientsignalsthatalteredtheglycosylationprogram,andreset
theIgGglycantotheprogramelicitedduringtheinitialrecognitionofantigen(A
inFigure6.1).
6.3 Futuredirections
Thishypotheticalmodelandtheresultsofthisdissertationprojectpointtomany
additional research questions that need to be answered to further refine and de-
scribetheregulationofIgGglycosylation. First,animalsstudiesofvaccinationwill
be required to confirm the results of ex vivo stimulations and determine whether
changesinGTexpressionresultinchangestoIgGglycosylation.
OurhypotheticalmodelofIgGglycosylationincludesparticularmechanismsof
regulationthatwehavebeguntoexplore,butrequirefurtherstudy. First,todeter-
minewhethermicroRNAsmayplayaroleinshuttingdownexpressionofparticu-
larGTs,weanalyzedmRNAexpressioninstimulatedBcellsovertimeandfound
that expression decreases within hours after addition of certain stimuli. We used
amicroRNAarrayplatformtoidentifypotentialmiRNAsthatareexpressedafter
stimulationandmaytargettheGTsinvolvedinIgGglycosylationandweidentified
142a few miRNAs as potential regulators of GTs based on their expression in B cells
after stimulation and their sequence-predicted targets (Figure 6.2). These three
miRNAs are excellent targets for further study to determine definitively whether
theyareimportantforregulationofIgGglycosylation.
An additional mechanism of GT regulation may be the expression and activa-
tionoftranscriptionfactorsthatactdirectlytoalterGTexpression. Inapilotstudy
toidentifypotentialtranscriptionfactors,weisolatedantigen-specificBcellsfrom
HIV-infected donors, including anti-gp120, -p24, and –HA antibodies and com-
pared the single cell transcriptional profiles of these cells to those of bulk B cells.
Usinganarrayof96genes,weidentifiedahandfuloftranscriptionfactorsandac-
tivation markers that correlate with the expression the GTs responsible for IgG
glycosylation. Interestingly,wealsoobservedthatthetranscriptionofsomegenes
diﬀersbetweenHIV-specificandflu-specificorbulkBcells,includingtheIgGgly-
cosylationGTs(Figure6.3A).Additionalanalysisrevealsasetoftranscriptionfac-
torsandBcellactivatingmoleculeswhoseexpressioncorrelatewithGTexpression
(Figure6.3B).Theseresultshighlightthepotentialrolefortranscriptionalregula-
tion of GTs by specific transcription factors in determining antigen-specific dif-
ferences in antibody glycosylation. Further work to establish the eﬀect of these
particularfactorsinGTexpressionremainstobedone.
Finally, a look into the potential epigenetic regulation of GT expression may
identify a further mechanism for controlling IgG glycosylation. A role for epige-
netic regulation of some glycosyltransferase has already been described [86, 120,
146], and the genome sequences of IgG glycosylation GTs contain large CpG is-
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Figure6.2: MicroRNAsareup-regulatedinresponsetoBcellstimulation. Three
miRNA targets, selected after a screen of 800 miRNAs are up-regulated in response to
the same stimulations that down-regulate B4GALT1 and ST6GAL1. Analysis of po-
tential miRNA targets by sequence specificity indicate a possible role for regulation of
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GBDUPSTBOE#DFMMTUJNVMBUJOHGBDUPSTDPSSFMBUFXJUIFYQSFTTJPOPG(5T
ǉǌǍlands (Figure 6.4), which could be targeted by DNA methylases to permanently
shut down gene transcription. Additional mechanisms of epigenetic regulation,
such as histone modifications, are also potential regulators of GT transcription.
Both of these types of modifications can be characterized through pull down as-
saysthatisolatesegmentsofchromatintoassessthelevelofDNAorhistonemod-
ificationsassociatedwithparticulargenes.
In addition to the regulatory mechanisms of IgG glycosylation, we have inter-
esting results that highlight novel potential roles for specific glycan structures in
determining antibody functionality. In particular, we have observed an associa-
tion between b-GlcNAc and complement recruitment and NK activation, which
canbefurtherexploredbyproducingantibodiesincellsthatareengineeredtoadd
b-GlcNActotheirIgGglycans. Usinggeneticengineering,IgGscontainingavari-
etyofglycanstructurescanbecreatedandtestedforfunctionalactivityfirstinour
existinginvitrofunctionalassays,andultimatelyinpassivetransferstudies,includ-
ingSIVandSHIVprotectionstudies. Theseexperimentswillbeespeciallyimpor-
tant given that the particular antibody eﬀector functions that are most protective
againstHIVorotherdiseasesremaintobedetermined. Furtherassessmentofthe
protectiveeﬀectsofantibodyeﬀectorfunctionsinanimalstudiesofSIVandSHIV
infection, as well as studies of human disease, will help to determine which eﬀec-
torfunctionsaremostimportantandwillprovideagoalfornewvaccinestrategies.
Oncethesefunctionsareidentified,theappropriatelyfunctionalIgGglycancanbe
selectedandelicitedusingaspecificsetofsignalsdeliveredduringvaccination.
The results of this work show that glycosylation is naturally regulated, possibly
146'JHVSF ȚȘ $Q( JTMBOET JO HMZDPTZMUSBOTGFSBTF HFOFT (FOF TFRVFODFT PG HMZDPTZM
USBOTGFSBTFT XFSF BOBMZ[FE GPS UIF QSFTFODF PG $Q( JTMBOET 	JO CMVF
 VTJOH UIF -J -BC
.FUI1SJNFS5PPM	6OJWFSTJUZ PG $BMJGPSOJB 4BO'SBODJTDP
 5SBOTDSJQUJPOBM TUBSU TJUFT
GPSFBDIHFOFBSFJOEJDBUFE
ǉǌǏthrough a combination of immune signals that can be harnessed during vaccina-
tion. Thesefindingsprovidethefoundationforfurtherworktodissectthemech-
anisms of IgG glycosylation regulation within B cells, and to identify the particu-
lar adjuvant preparations that best tune IgG glycans. Ultimately, modification of
IgGglycosylationmayprovetobeanessentialpartofasuccessfulvaccinestrategy
againstHIVtoelicitprotectivenon-neutralizingantibodies.
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